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ABSTRACT 
Chronic infection of the Hepatitis B Virus (HBV) is believed to be one of the most 
potent etiological factors for hepatocellular carcinoma, which is the second leading 
cause of cancers for the past dccade in Hong Kong. Hepatitis B virus X antigen (HBx) 
is a 17-kDa protein encoded by one of the four open reading frames of the H B V 
genome. HBx is a transactivator that exerts its functions through protein-protein 
interactions. Known interacting partners includc the p53 tumour suppressor protein. 
A novel HBx-Interacting Protein (XIP) was discovered by yeast two-hybrid screening. 
It was demonstrated that XIP is able to bind HBx and inhibit H B V replication. As a 
first step towards the structure-function studies of HBx and XIP, the over-expression 
and purification protocols for the two proteins were reported. HBx was expressed in 
two forms: a six-histidine-tagged fusion protein (6xHis-HBx) and a non-fusion version 
(HBx). Despite extensive efforts in optimizing the expression conditions, both forms 
of HBx expressed solely as inclusion bodies in Escherichia coli. 6xHis-HBx was purified 
by metal-chela ting affinity chromatography prior to refolding, which was achieved via 
sequential removal of urea by dialysis. 6xHis-HBx was unstable and precipitated at 
concentration >0.4 mg/ml. The instability of 6xHis-HBx was probably due to the 
presence of large molecular weight aggregates of HBx, which was not removed by the 
metal-chelating affinity column. The use of size-exclusion chromatography to purify 
HBx resulted in a much more stable protein sample, which was used subsequently for 
structural characterization. The circular dichroism (CD) spectrum of HBx suggested 
that the protein adopts ~3()% helix and ~20% sheet. The chemical unfolding curve of 
HBx resembles a two-state transition and its stability, measured by free energy of 
unfolding, was 13 kj/mol at 25°C. XIP was expressed in a soluble form and was 
purified by hydrophobic interaction and size-exclusion chromatography. C D and 
nuclear magnetic resonance (NMR) experiments showed that XIP is unstructured. 
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Introduction 1 
Chapter 1 Introduction 
1.1 Epidemiology of Hepatitis B Virus (HBV) 
The epidemiological evidence has suggested that chronic infection of hepatitis B virus 
(HBV) is a major risk for the development of hepatocellular carcinoma (HCC). In 
2001, there are estimated to be 387 million carriers of H B V in the world and 
one-quarter of them will develop H C C (Arbuthnot et al., 2001). While chronic carrier 
of H B V is relatively uncommon in developed countries, shown in Fig 1.1.1，it is epidemic 
in Chinese. Compared with the non-HBV carriers, chronic H B V carriers have a 100-fold 
increased chance for developing HCC. The most important thing is that H C C is one of 
the major global malignant diseases nowadays and it ranks fifth in the overall frequency. 
The geographical distributions of chronic H B V infection and H C C are closely similar 
(Kew, 1981; IRAC, 1994) suggested that the virus may be the cause of the tumor. 
Nevertheless, the mechanism of virus-induced transformation of hepatocyte remains in 
doubt. 
Global Distribution of Chronic 
Hepatitis R Infection mmm 
H H 
• >8% • Higli 2%. 7% • <2% - Low 
Intermediate Fig 1.1.1 一 Global distribution of chronic hepatitis B infection 
{Adopted from http://vvww.globalserve.net/) 
Area showed in red means over 8 % of the population was infected by HBV; area 
shown in yellow means around 2 to 7 % of the population was infected by HBV; area 
shown in green means less than 2 % of the population was infected by HBV. 
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1.2 Relationship between Hepatitis B Virus and Hepatocellular Carcinoma 
The way that H B V induces H C C is still uncertain. However, it has been proposed that 
chronic inflammation induced by H B V may lead to necrosis of hepatocytes. 
Regeneration of liver cells may accumulate harmful mutations that cause H C C to 
develop finally. Another hypothesis argues that the integration of H B V genome into 
the host genomic D N A may disturb the control of cellular gene expression and thus the 
infected cell will proliferate and differentiate continuously (Yaginuma et al.’ 1987; 
Takada et al, 1990). On the other hand, accumulating evidence suggests that the viral 
protein (Hepatitis B Virus X Protein, HBx) of H B V is oncogenic and is capable of 
accelerating progression of H C C development (Koike et al�2002). 
1.3 Brief Description of HBV Genome 
The human hepatitis B virus is the archetype of the hepadnavirus family, Hepadnamidae. 
Other members of the hepadnaviridae family include duck hepatitis B virus (DHBV)’ 
ground squirrel hepatitis virus (GSHV), snow goose hepatitis B virus (sgHBV)， 
woodchuck hepatitis vims (WHY), and wooly monkey hepatitis virus. The genome of 
hepadnavirus is highly conserved. It is approximately 3.2kb in length, circular and 
partially double-stranded (Francki et al.’ 1991). In the world of viruses, the H B V 
genome is unique due to its compact nature, use of overlapping reading frames and 
dependence on a rcverse-ti-anscriptional step for replication. There are four 
overlapping open reading frames (ORFs) in the genome and they result in the 
transcription and expression of the different hepatitis B proteins through the use of 
varying in-frame start codons (Fig 1.3.1). The O R F 1) encodes the hepatitis B 
polymerase protein. The O R F S encodes the three surface proteins. The O R F C 
HBV Genome ^ ^ H 
,7 ‘止 ^ ^ ^ ^ H 
/ DRl 1824-1835 
Enhl 1000-I20D 
Enh2 
Genomic RW A 
10。1 • H ^ l l h — — ! • 1561 
DRl 
^ Poly A Signal  
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1.4 Possible Roles of HBx in Hepatocellular Carcinoma 
The H B V X gene encoded the HBx protein, which is 17-kDa in size and is composed 
of 154 amino acids (Fig 1.4.1). This gene is conserved among all mammalian 
hepadnaviruses, which is essential for viral infection and viral replication. Studies of 
HBx have been carried out in both in vitro and in vivo experiments. Alternative 
translation of HBx gene from an embedded promoter inside its O R F can produce a 
truncated HBx that can transactivate some R N A polymerase promoters (Kwee et al.’ 
1992; Zhang et al” 1994). It has been reported that HBx forms dimers in its natural 
occurring state. This phenomenon is supported by the detection of HBx dimers on 
non-reducing SDS-PAGE (Autunovic et aL, 1993) and the finding shows that the 
amino-terminal regulatory domain of HBx can associate itself or the full length of HBx 
by far-western blotting analysis (Murakomi et al.�1994). Therefore, HBx may need 
oligomerization for its function. 
Fig 1.4.1 一 The protein structure of HBx presented in a schematic diagram 
(Adopted from http://www. globalserve. net/} 
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The tumor suppressor p53 is a well-known interacting partner of HBx. Their 
interaction was proven by co-immunoprecipitation in a liver sample of a H C C patient 
(Feitclson et al., 1993). It has been suggested that HBx modifies p53 function by acting 
as a p53 adaptor (Cromlish, 1996) - it either interferes with the nuclear transportation of 
p53 in response to D N A damage or blocks the downstream pathways of p53 in 
arresting a cell or inducing cell suicide in the case of mutations occurs during 
chromosome replication. On the other hand, the transcription factors of the bZIP 
family could also be the targets for HBx. The bZIP family members participate in lots 
of cell functions including proliferation, transformation to differentiation and growth 
arrest. HBx activates CREF ATF-2 by promoting the formation of high affinity D N A 
binding form CREF ATF-2 and thus turns on some oncogenes or growth factors and 
results in cell proHferation. Also, HBx indirectly activates A I M through the activation 
of the M A P K / E R K cascade. Moreover, HBx is implicated in regulating Spl mediated 
transcription of an insulin-like growth factor II (IGF-II). 
In a recent transgenic study, 80% of transgenic mice harboring the HBx gene developed 
H C C or adenoma, suggesting a strong link between HBx and hepatocarcinogenesis 
Koike et "/•’ 2002). They argued that HBx disrupts the equilibrium maintained between 
proliferation and apoptosis of hepatocytes, and hence accelerates H C C development 
without accumulation of a complete set of gene mutations (Koike et aL, 2002). The 
capability of HBx in accelerating of hepatocytes proHferation has also been observed in 
a cell culture system (Koike et al.�1994). 
However, HBx is not easily detected in hepatocarcinoma (HCC) tissues nor m active 
H B V infected cells because their expression level is generally very low. Though many 
biological / cellular functions have been associated with HBx, their validity remains in 
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question simply due to the low levels of HBx seen in infected cells. In conclusion, the 
nature and function of the HBx protein remain to be characterized. 
1.5 Novel Interacting Partner of HBx - HBx-Interacting Protein (XIP) 
The HBx-Interacting Protein (XIP) was identified by the yeast two-hybrid system through 
screening of a c D N A library which was derived from a hepatocellular carcinoma cell line 
using a HBx fusion bait (Melegari et aL, 1998). XIP is a 9.6-kDa protein that can bind 
HBx and inhibit the wild-type hepatitis B virus replication (Melegari et aL�1998). Their 
interaction was also confirmed by in vitro binding assay using E. coli to express HBx and 
GST-XIP proteins (Melegari et aL, 1998). The knowledge of XIP was very limited, 
however, this novel protein was widely expressed in various human tissues such as heart, 
brain，placenta, lung, liver, skeletal muscle, kidney and pancreas (Melegari et aL, 1998). 
1.6 Objectives 
The functions of HBx within the cells and its interaction with XIP are still not clearly 
understood. As a pre-requisite for studying the structure-function of HBx and XIP, 
here we report the over-expression and purification of the two proteins. The 
structures of the purified proteins were then characterized by biophysical methods such 
as circular dichroism (CD) and nuclear magnetic resonance (NMR). 
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Chapter 2 Methodology 
2.1 Information of the HBx and XIP Clones 
Both c D N A clones, HBx and XIP, were bought from the vVmerican Type Culture 
Collection (ATCC). The A T C C numbers for Hepatitis B Virus X Protein (HBx) and 
HBx-Interacting Protein (XIP) clones are 45020 and 555480 respectively. The 
sequences of both HBx and XIP are listed in the part of Appendix I . 
2 . 2 In fo rmat ion o f t h e Express ion V e c t o r s (pRSETA, 6xHis-pRSETA and pET8C) 
The pRSEl A vectors (Invitrogen) were modified to remove the 17 gene 10 leader, the 
Xpress'M Epitope and the E K cleavagc site to create pRSETA-NoHis and 
pRSElV\-6xHis (Appendix E). The HBx c D N A was cloned into the two vectors, 
both are modified version of pRSRTA from Invitrogen (Appendix III). The XIP 
c D N A was cloned into pET8C，which was obtained from Novagen. All these vectors 
were constructed with '17 promoter, M C S and Ampicillin Resistance Gene for selection 
in E. coli. The vector map, polylinker sequence, vector sequence in text format and 
vector restriction map of these three vectors were all included in Appendix HI • 
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The information about the vectors for subcellular localization (pECFP-Cl, pEGFP-Cl 
and pEYFP-Cl) and the vectors for the Yeast Two-Hybnd (pGBKT7 and pACT2) assay 
were listed in Appendix IH. 
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2.3 Sub-Cloning of HBx and XIP into Different Vectors 
2.3.1 Design of Primers for Cloning of HBx and XIP into Different Vectors 
BamHI was the first restriction site found in the polylinker of the modified pRSETA 
vectors. Therefore, to minimize coding sequence from the cloning vector, BamHI 
should ideally be used. However, there is a BamHI site present within the HBx coding 
sequence (Fig 2.3.1). Bglll, which creates compatible sticky ends (Fig 2.3.2), was 
used instead of BamHI on the primer designed for HBx sub-cloning. The table below 
listed all primers used for HBx and XIP sub-cloning into different vectors: 
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Table 2.3.1 List of all primers used for HBx and XIP cloning 
Vector for Cloning Primer Sequence  
HBx-F pRSETA/pRSETA (6x His) 5' - TAGGGCAGATCTGCTGCTCGGATGTGCTGCAAACTG - 3’ 
HBx-R pRSETA/pRSETA (6x His) 5, - TAGGGCGAATTCTTAGGCAGAGGTGAMAAGTTGCATGG - 3’ 
XIP-F pET8C 5’ - TAACTACCATGGAGGCGACCTTGGAG - 3’ 
XIP-R pET8C 5, - TAACTAGGATCCTCAAGAGGCCATTTTGTG - 3’ 
HBx-F pECFP/GFP/YFP-C1 5’ - TAGGGCAGATCTGCTGCTCGGATGTGCTGCAAACTG - 3' 
HBx-R pECFP/GFP/YFP-C1 5，- TAGGGCGAATTCTCATTAGGCAGAGGTGAAAAAGTTGCATGG - 3' 
XIP-F pECFP/GFP/YFP-C1 5' - TAACTAAGATCTGAGGCGACCTTGGAG - 3, 
XIP-R pECFP/GFP/YFP-C1 5' - TAACTAGAATTCTCAAGAGGCCATTTTGTG - 3, 
XIP-F pACT2r 5, - TAACTACCATGGAGGCGACCTTGGAG - 3’ 
XIP-R pACT2 5, - TAACTAGGATCCTCAAGAGGCCATTTTGTG - 3' 
• Sequence in green color refers to the start codon 
• Sequence in purple color refers to the stop codon 
• Sequence in red color refers to the start Bg/II restriction site 
• Sequence in orange color refers to the start EcoRI restriction site 
• Sequence in skv blue color refers to the start Ncol restriction site 
• Sequence in blue color refers to the BamHI restriction site 
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1 ATG GCT GCT CGG ATG TGC TGC AAA CTG GAT CCT TCG CGG GAC GTC 45 
1 Met Ala Ala Arg Met Cys Cys Lys Leu Asp Pro Ser Arg Asp Val 15 
Fig 2.3.1 • HBx sequence with a BamHI restriction site 
Sequence showed in pink color is the BamHI restriction site, 
which is located at 27 to 32 base pair in the HBx sequence. 
Enzyme BgUI BamHI 
5，A^GATC T 3， 5，C7GATC C 3， Recognition Sequence 
3' T C T A G ^ 5' 3， C C T A G f 5， 
Fig 2.3.2 - Bglli and BamHI recognition sequence and restriction site 
The two enzymes recognized difference sequence but they both produce 
the same sticky end 5' GATC 3'. 
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2.3.2 Polymerase Chain Reacton (PGR) Protocol 
The standard PGR reaction mix (50 |xL reaction) was showed below. All reactions were 
run for 30 cycles. 
Table 2.3.2 PGR reaction components 
Components Volume Final Concentration 
Autoclaved ultra-filtered water (pH 7.0) 41.5 f.iL -
10x PGR Buffer* 5 |iL 1x 
dNTPs mix (1 OmM each nucleotide) 1 |_iL 200 i^M (each nucleotide) 
Forward Primer (100 pmoles/pL) 1 0.2 |aM 
Reverse Primer (100 pmoles/jjL) 1 |_iL 0.2 inpM 
Pfu DNA Polymerase 0.5 i^L 1.5 Unit/50 |uL  
DNA template (500 ng/^jL) 0.25 |liL 125 ng/50 
The Pju D N A Polymerase was supplied by Promega (Cat. No.: M77745). For the PGR 
buffer, it was provided together with the Pju D N A Polymerase. The lOx PGR buffer 
contains: 200 m M Tris-HCl (pH 8.8 at 25"C), 100 m M KCl, 100 m M (NH4)2S〇4’ 20 m M 
MgS〇4，1 % Triton®X-100 and 1 mg/ml nuclease free BSA. 
The requirement of an optimal PGR reaction was to amplify a specific locus without 
any non-specific by-products. Therefore, annealing needed to take place at a 
sufficiently high temperature to allow only the perfect D N A - D N A matches to occur in 
the reaction. For any given primer pair, the PGR program could be selected based on 
the composition (GC content) of the primers and the length of the expected PGR 
product. Also, "Hot Start" of the PGR was performed - Template D N A was 
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denatured at 94"C prior to polymerase addition. The activity of the P/u D N A 
polymerase was about 500 nucleotides/minute at optimal temperature (72~74"C) and 
the extension time in the reaction could be calculated accordingly. All the PGR was 
performed with the Gene A m p PGR System 2400, Applied Biosystems. Table 2.3.3 
summarized the PGR profile for the amplification of HBx and XIP fragments. 
HBx (454 bps) XIP (273 bps) 
Program Details  
Temperature Time Temperature Time 
First denaturing 94°C 5min 94°C 5min Polymerase 
Denaturing “ 94�C 30 sec 94�C 
Annealing 58°C 30 sec 55°C 30 sec > 30 Cycles 
Extension 72°C 1 min 72°C 45 sec J 
Last extension 72�C 10 min 72°C 10 min 
Storage 4 � C oo 4°C oo 
Table 2.3.3 • HBx and XIP PCR Profiles 
The extension time (in minutes) required was calculated from the size of the product to be 
amplified. A 5-minute denaturing step was used before the actual cycling starts. An 
annealing time of 30 seconds was sufficient for all primer pairs. The annealing 
temperature chosen was based on the melting temperature of the primers. Also, a final 
extension time of 10 minutes was employed to help finish the elongation of most PCR 
products initiated during the last cycle. In general, 30 cycles should be sufficient for usual 
PCR reactions. 
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2.3.3 Enzyme Digestion Protocol 
As mentioned before, different restriction sites were designed within the primer 
sequence for sub-cloning. Table 2.3.4 listed all restriction sites that were used in the 
vector and the insert for cloning. Usually, an enzyme digestion reaction mixture 
contained the required enzymes, the buffer provided together with the enzymes, the 
inserts or the vectors and finally the autoclaved water to bring up the reaction mixture 
to a desirable volume. The digestion mixture was then incubated at 37"C for 3 to 4 
hours. Tables 2.3.5 a & 2.3.5 b listed the enzyme digestion reaction profile for HBx 
and XIP cloning into different vectors. 
Restriction Sites Used Vectors HBx inserts 
pRSETA (No Fusion) BamHI & EcoRI Bglll & EcoRI 
PRSETA (With His-Tag) BamHI & EcoRI Bglll & EcoRI 
PECFP-CI Bglll & EcoRI Bglll & EcoRI 
PEGFP-CI Bglll &E(X)RI Bglll & EcoRI 
PEYFP-CI Bglll & EcofRI Bglll & EcoRI 
Restriction Sites Used Vectors XIP Inserts 
pET8C BamHI & Ncol BamHI & Ncol 
PECFP-CI Bglll & EcoRI Bglll & EcoRI 
PEGFP-CI Bglll & EcoRI Bglll & EcoRI 
PEYFP-CI Bglll & EcoRI Bglll & EcoRI  
PACT2 BamHI & Ncol BamHI & Ncol 
Table 2.3.4 - Summary of the restriction sites used in the HBx 
insert, XIP insert and different vectors including expression 
vectors, fluorescent protein vectors and MATCHMAKER vectors 
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Table 2.3.5 a H B x E n z y m e Diges t ion React ion Prof i le 
Components HBx PGR pRSETA pRSETA (6x His) pECFP-C1, pEGFP-C1, pEYFP-C1 
Autoclaved H2O - 9 laL 9 11 |liL 
BamHI (10U/^I) - 1 |iL 1 pL -
Bglll (10U/^I) 1|liL - - 1 (iL 
EcoRI (20U/^ I) 1 laL 1 |iiL 1 ^ L 1 ^ L 
1 0 X B S A - 2).IL 2|AL -
10X NEB Buffer No (3), 2 |iL No (2), 2 |LIL NO (2), 2 |iL No (3), 2 i^L 
DNA 16|iL 5nL 5 i^L 5 |iL 
Total Volume 20 |LIL 20 |LIL 20 20 \il 
Table 2.3.5 b X I P E n z y m e Diges t ion React ion Prof i le 
XIP cloned into pET8C and pACT2 XIP cloned into pECFP/GFP/YFP-C1 
Components  
XIP PGR pET8C pACT2 XIP PGR pECFP/GFP/YFP-C1 
Autoclaved H2O — 9 |iL 9 i^ L — 11 
BamHI (10U/^I) 1 |_iL 1 ^L 1 i^L - -
Bglll (lOU/^il) — - - 1 |iL 1 i^ L 
EcoRI (20U/^I) - - - 1 nL 1 |iL 
Ncol (10U/^I) 1 |_iL 1 l_iL 1 l_iL - -
1 0 X B S A 2|.IL 2|LIL 2 ^IL … … 
10X NEB Buffer No (2), 2 i^L No (2), 2 |iL No (2), 2 … No (3), 2 |aL No (3)，2 i^L 
DNA 14 nL 5|iiL 5 ^L 16 i^L 5 |iL 
Total Volume 20 |_iL 20 |xL 20 |iiL 20 fiL 20 i^L 
Table 2 .3 .5 - E n z y m e d igest ion react ion profi le for H B x a n d X I P c lon ing 
The reaction mixtures were incubated at 2>7°C for 3 to 4 hours. The 
digested products were analyzed by agarose gel electrophoresis and 
recovered by gene clean, (a) HBx and its cloning vectors enzyme digestion 
profile; (b) XIP and its cloning vectors enzyme digestion profile. 
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2.3.4 Ligation Protocol 
The T4 D N A ligase used was supplied by New England BioLabs Inc. (Cat. No.: 
M0202S). The lOX T4 D N A Ligase Buffer contained 500 m M Iris HCl, 100 m M 
MgCls, 100 m M DTT, 10 m M ATP, 250 |ug/ml BSA, (pH 7.5 at 25。C). The cohesive 
inserts from an enzyme digestion of the PGR products were ligated into the digested 
vectors at a 3:1 (insert : vector) molar ratio. Table 2.3.6 showed the ligation protocol 
of HBx and XIP into different vectors. Usually, the ligation reaction was performed at 
14"C overnight 16 hours). 
Table 2.3.6 HBx and XIP Ligation Reaction Profile 
Components Ligation Reaction Control 
Autoclaved H2O — 14 \xl 
Insert 14 juL — 
Vector 3 nL 3 fiL 
10X Ligation Buffer 2 i^L 2 ^ 1 
T4 DNA Ligase 1 |iL 1 pL 
Total Volume 20 |LIL 20 |iL 
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2.3.5 Preparation of Competent Cells 
Two buffers should be prepared prior to the preparation of any types of E. coli 
competent cells. They were RFl (30 m M KAc，100 m M RbCl。，10 m M CaCl,, 50 m M 
MnCl2, 15 % glycerol, pH was adjusted to 5.8 with acetic acid (HAc), the solution was 
sterilized by filtration using Steritop bottle top filter units with 0.22 \xm Durapore 
(PVDF) membrane and was stored at 4"C) and RF2 (10 m M MOPS, 10 m M RBCl,, 75 
m M CaCl2, 15 % glycerol, pH was adjusted to 6.5 with K O H , the solution was sterilized 
by filtration using Steritop bottle top filter units with 0.22 ^ m Durapore (PVDF) 
membrane and was stored at 4"C). 
Firstly，E. coli (DH5a, or C41 (DE3)) was streaked from the frozen stock (stored at 
-70"C) to a LB agar plate. The newly streaked bacteria were allowed to growth at 37"C 
for 16 hours. Then, several single colonies were picked and inoculated into 5ml LB 
medium. The bacterial culture was incubated at 37"C, 280 rpm until the O D at 600 
n m reached 0.3〜0.4 (〜31ir). After that, the starter culture was inoculated into 100 ml 
of lb medium. The culture was allowed to grow at 37"C, 280 rpm until the O D at 
600 n m reached 0.4〜0.5 (~2hr). Next, the culture was immediately chilled on ice for 5 
min. The cells were harvested by centrifugation at 5000 rpm for 10 min at 4"C,. The 
pellet was then resuspended in 40 ml RFl and kept on ice for 5 min. The suspension 
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was re-centrifuged at 5()()() rpm for 10 min at 4')C The pellet was resuspended in 4 ml 
RF2 and kept on ice for 15 min. The competent cell aliquots (100 |il) were snapped 
frozen in liquid nitrogen and were stored at -70"C until use. 
2.3.6 Transformation 
The ligation products were transformed into E. coli Strain D H 5 a to obtain the 
recombinant plasmids. 
Firstly, a 100 jul aliquot of E. coli Strain D H 5 a competent cells was thawed on ice. 
All the ligation mixture (20 was added into the competent cells and mixed gently by 
pipetting up and down. The bacterial mixture was then incubated on ice for 30 
minutes. After that, the bacterial mixture was heat shocked for 2 minutes at 42°C, 
followed by chilling on ice for 10 minutes. Luria Broth media (400 |al) was added into 
the bacterial mixture and incubated at 37°C for 45 minutes. After 45 minutes 
incubation, all the bacterial mixture was spun down and 400 )l11 medium was removed. 
The remaining 100 )li1 bacterial culture was spread onto the appropriate solid medium 
(i.e. LB plates with different antibiotics for selection of successful ligation products). 
Finally, the plate was incubated overnight 16 hours) at 37°C. 
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2.3.7 Gel Extraction Protocol 
2.3.7.1 Life Technologies CONCERT™ Rapid Gel Extraction System 
(Cat. No.: 11456-27, Modified from the provided protocol) 
An aliquot of the T E Buffer (TE) was preheated to 70"C using a water bath or a heat 
block. The gel containing the D N A fragment was excised out using a clean, sharp 
blade and placed into a 1.5-ml microcentrifuge tube. The gel slice was weighted and 30 
)il of Gel Solubilization Buffer (LI) was added for every 10 mg of gel. Next, the gel 
slice was incubated at 50"C until the gel slice was completely dissolved. The gel 
mixture was pipetted into the spin cartridge, which was already in a 2-ml wash tube. 
The mixture was then centrifuged in a microcentrifuge at > 12,000 x g for 1 min. The 
flow-through was discarded. After that, the cartridge was placed back into the 2-ml 
wash tube and 500 |al of Gel Solubilization Buffer (LI) was added to the spin cartridge. 
The cartridge was incubated at room temperature for 1 min, and then was centrifuged at 
> 12,000 X g for 1 min. Again, the flow-through was discarded. The cartridge was 
placed back into the 2-ml wash tube, 700 |il of Wash Buffer (L2) (containing ethanol) 
was added to the spin cartridge and incubated for 5 min at room temperature. The 
cartridge was centrifuged at > 12,000 x g for 1 min. The flow-through was discarded 
and the cartridge was centrifuged again for 1 min to remove residual wash buffer. 
Methodology 20 
Finally, D N A was eluted out by adding 35 |ul of TE Buffer (VE), pre-warmed at 70"C, 
directly to the center of the spin cartridge in a 1.5-ml recovery tube. The cartridge was 
allowed to incubate at room temperature for 1 min, and then the cartridge was 
centrifuged at > 12,000 x g for 2 min. 
2.3.7.2 QIAGEN Gel Extraction Kit 
(Cat. No.: 28706，Modified from the provided protocol) 
All centrifugations were performed at 13,000 rpm in a conventional table-top 
microcentrifuge. The D N A fragment from the agarose gel was excised out with a 
clean, sharp scalpel. The gel slice was weighted in a colorless tube and 3 volumes of 
Buffer Q G was added to 1 volume of gel. For example, 30 |il of Buffer Q G for every 
10 m g of gel. Then, the gel slice was incubated at 50"C until the gel was completely 
dissolved. After the gel slice was dissolved completely, the color of the mixture should 
be yellow indicating the pH of the mixture was optimal for D N A binding onto the 
column. Next, 1 gel volume of isopropanol was added to the sample and mixed. In 
order to bind D N A , the sample was applied to the QIAquick column, which was placed 
in a 2-ml collection tube, and centrifuged for 1 min. The flow-through was discarded 
and the QIAquick column was placed back in the same collection tube. Buffer Q G 
(0.5 ml) was added to the QIAquick column to remove all traces of agarose and 
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centrifuged for 1 min. Buffer PE (0.75 ml) was added to the QIAquick column to 
wash away salts and centrifuged for 1 min. To remove residual ethanol from Buffer 
PE, the flow-through was discarded and the QIAquick column was centrifuged again 
for an additional 1 min. Finally, the QIAquick column was placed into a clean 1.5-ml 
microcentrifuge tube, 35 i^l Buffer EB or water was added to the center of the 
QIAquick membrane and the column was let stand for 1 min before centrifugation. 
The D N A was then eluted from the QIAquick column using 35 jal of Buffer EB or 
autoclaved H^Cl 
Methodology 22 
2.3.8 Plasmid Preparation Protocol 
2.3.8.1 Life Technologies CONCERT™ Rapid Plasmid Minipreps 
(Cat. No.: 11453-024, Modified from the provided protocol) 
Firstly, 5 ml of an overnight culture was spun down and all medium was thoroughly 
removed. Next, 250 |LI1 of Cell Suspension Buffer (Gl) (containing RNase A) was 
added to the pellet and the cells were suspended until homogeneous. 250 fil of Cell 
Lysis Solution (G2) was added to the cell suspension and was mixed gently by inverting 
the capped tube five times. The lysate was then incubated at room temperature for 5 
min. After incubation, 350 |il of Neutralization Buffer (M3) was added and mixed 
immediately by inverting the tube five times. The mixture was centrifuged at > 12,000 
X g for 10 min. The supernatant from the previous step was loaded into the spin 
cartridge, which was already placed in a 2-ml wash tube. The cartridge was centrifuged 
at > 12,000 X g for 1 min and the flow-through was discarded. The cartridge was 
placed back into the 2-ml wash tube and 500 [i\ of Optional Wash Buffer (GX) was 
added to the spin cartridge. Then, the cartridge was incubated at room temperature 
for 1 min and after that it was centrifuged at > 12,000 x g for 1 min. The 
flow-through was discarded. Again, the cartridge was placed back into the 2-ml wash 
tube. Then, 700 )al of Wash Buffer (G4) (containing ethanol) was added to the spin 
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cartridge. The cartridge was centrifuged at > 12,000 x g for 1 min. The 
flow-through was discarded. Next, the cartridge was placed back into the wash tube 
and centrifuged again at > 12,000 x g for 1 min to remove residual wash buffer. Finally, 
the cartridge was placed into 1.5-ml recovery tube, 75 |al of warm T E Buffer (TE) was 
added directly to the center of the spin cartridge and was incubated at room 
temperature for 1 min. Finally, the plasmids were eluted out by centrifugation at > 
12,000 X g for 2 min. 
2.3.8.2 QIAGEN Plasmid Maxi Kit 
(Cat. No.: 12263, Modified from the provided protocol) 
Firstly’ a single colony from a freshly streaked selective plate was picked and inoculated 
into 2-5 ml LB medium containing the appropriate selective antibiotic. The starter 
culture was grown for 〜8 h at 37()C with vigorous shaking (-300 rpm). The starter 
culture was then diluted (1/500 to 1/1000) into selective LB medium. For high-copy 
plasmids, 25 ml or 100 ml medium was inoculated. For low-copy plasmids, 100 ml or 
500 ml was inoculated. The bacterial culture was then allowed to grow at 37"C for 12 
to 16 h with vigorous shaking (〜300 rpm). O n the next day, the bacterial cells were 
harvested by centrifugation at 6000 x g for 15 min at 4"C. The bacterial pellet was 
resuspended in 10 ml Buffer PI. Then, 10 ml of Buffer 1)2 was added and mixed 
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gently but thoroughly by inverting 4 - 6 times. After that, 10 ml of chilled Buffer P3 
was added and was mixed immediately but gently by inverting 4 — 6 times. The 
neutralized cell lysate was incubated on ice for 20 min. In order to separate the 
supernatant and the pellet, the lysate was centrifuged at > 20,000 x g for 30 min at 4"C. 
Then, the supernatant containing plasmid D N A was removed promptly. Next, the 
supernatant was re-centrifuged at > 20,000 x g for 15 min at 4"C. The supernatant 
containing plasmid D N A was removed promptly. During the centrifugation process, a 
QIAGEN-tip 500 was equilibrated by applying 10 ml Buffer QBT, and the column was 
allowed to empty by gravity flow. Then, the supernatant from the previous step was 
applied to the QIAGEN-tip and it was allowed to enter the resin by gravity flow. In 
order to remove the non-plasinid D N A contaminants, the QIAGEN-tip was washed 
with 30 ml Buffer Q C for two times. Then, D N A was cluted with 15 ml Buffer QF. 
To increase the purify and the concentration of plasmid D N A , the eluted D N A was 
precipitated by adding room temperature isopropanol (10.5 ml). The D N A mixture 
was mixed and centrifuged immediately at > 15,000 x g for 30 min at 4"C. The 
supernatant was decanted carefully. Next, the D N A pellet was washed with 5 ml of 
room temperature 70% ethanol, and was centrifuged at > 15,000 x g for 10 min. 
Again, the supernatant was decanted carefully without disturbing the pellet. Finally, 
the pellet was air-dried for 5 -10 min, and the D N A was re-dissolved in a suitable 
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volume of buffer (e.g. TE, pH 8.0, or 10 m M Tris-Cl, pH 8.5). 
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2.4 Exptession of HBx and XIP in E. co/i Strain C41 (DE3) 
2.4.1 Transfotmation 
The expression plasmids were transformed into competent cells of E. coli Strain C41 
(DE3) prior to protein expression. 
Firstly, a 100 jul aliquot of FL coli Strain C41 (DE3) competent cells was thawed on ice. 
2 plasmid was added into the aliquot of competent cells and was mixed gently by 
pipetting up and down. Next, the bacterial mixture was incubated on ice for 30 
minutes. Then, the bacterial mixture was heat shockcd for 2 minutes at 42°C, followed 
by chilling on ice for 10 minutes. Luria Broth media (400 |LI1) was added into the 
bacterial mixture and incubated at 37°C for 45 minutes. After 45 minutes incubation, 
different dilution folds of the bacterial culture were spread on the appropriate solid 
medium plates (i.e. Luria Broth plates with different antibiotics for selection of 
appropriate plasmids). The plate was incubated overnight 16 hours) at 37°C. 
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2.4.2 Expression of HBx and 6xHis-HBx in E. co/r Strain C41 (DE3) 
Both types of Hepatitis B Virus X Protein (6xHis or N o fusion) were expressed in E. 
coli Strain C41 (DE3) using the same protocol. Firstly, the competent cells were 
transformed with HBx-pRSETA and 6xHis-HBx-pRSETA. Single colonies of 
transformed bacteria were picked into 25 ml of M 9 Z B medium containing 0.1 mg/ml 
ampicillin. The starter culture was then incubated at 37"C, 280 rpm for 3 hours. 
After 3 hours, 2 ml starter culture was taken out, spun down and the pellet was stored 
at -2()"C for plasinid preparation and protein analysis by SDS-PAGE. Starter culture 
(10 ml) was inoculated to 1 liter M9ZB medium with ampicillin. The expression 
culture was allowed to grow at 37"C, 280 rpm until OI )_ 二 0.4 - 1.0 (〜2.5 hours). 
Again, 2 ml expression culture was taken out, spun down and the pellet was stored 
at -20"C for plasmid preparation and protein analysis by SDS-PAGE. Then, 1 ml of 
0.4 M IPTG (Final [IPTG] = 0.4 m M ) and 1 ml of 100 mg/ml ampicillin (Final 
[Ampicillin] = 0.1 mg/ml) were added. The expression culture was left to grow at 
37"C, 280 rpm overnight (16 〜24 hours). On the next day, 2 ml expression culture 
was taken out and spun down and the pellet was stored at —20"C for plasmid 
preparation and protein analysis by SDS-PAGE. All the remaining culture was spun 
down at 4"C, 6000 rpm and 10 minutes for further experiments. 
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2.4.3 Expression of XIP in E. coi?'Strain C41 (DE3) 
The Hepatitis B Virus X Interacting Protein was expressed in E. coli Strain C41 (DE3). 
Firstly, the competent cells were transformed with XIP-pET8C. Single colonies of 
transformed bacteria were picked into 25 ml of M 9 Z B medium (For non-labeled 
proteins, Appendix VH) or M 9 medium + '^NH^Cl (For labeled proteins, Appendix VE) 
containing 0.1 mg/ml ampicillin. The starter culture was then incubated at 37"C, 280 
fpm for 3 hours. After 3 hours incubation, 2 ml starter culture was taken out, spun 
down and the pellet was stored at -20"C for plasmid preparation and protein analysis by 
SDS-PAGE. Starter culture (10 ml) was inoculated to 1 liter M 9 Z B medium with 
ampicillin. The expression culture was allowed to grow at 37"C, 280 rpm until 〇D_ 
二 0.4 — 0.6 2.5 hours). Again, 2 ml expression culture was taken out, spun down 
and the pellet was stored at -20"C for plasmid preparation and protein analysis by 
SDS-PAGE. Then, 1 ml of 0.4 M IPTG (Final flPTG] = 0.4 m M ) and 1 ml of 100 
mg/ml ampicillin (Final [ Ampicillin] = 0.1 mg/ml) were added. The expression 
culture was left to grow at 37"C, 280 rpm overnight (12 〜16 hours). O n the next day, 
2 ml expression culture was taken out, spun down and the pellet was stored at 一20('C for 
plasmid preparation and protein analysis by SDS-PAGE. All the remaining culture was 
spun down at 4"C, 6000 rpm and 10 minutes for further experiments. 
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2.5 Preparation of Buffers for Chromatogtaphy and Circular Dichroism 
Spectrum Measurement 
All buffers used for any type of chromatography and circular dichroism spectrum 
measurement were filtered through Steritop bottle top filter units with 0.22 f^m 
Durapore (PVDF) membrane and degassed before use. It is because any dust particles 
or insoluble precipitates could interfere with the reading measured by 
spectrophotometers. Also, air bubbles present inside the sample could affect the 
column performance. 
2.6 Purification and Refolding of HBx and His-Tagged HBx 
2.6.1 Washing of HBx and His-Tagged HBx Inclusion Bodies 
The purpose of washing the inclusion bodies of HBx proteins was to remove any 
membmne-bound proteins and lipids. Firstly, cell pellet from one-liter culture was 
resuspended with 40 ml of 50 m M 1)13’ pH 7.4 or other low salt buffer with similar pH. 
The resuspended cells was sonicated with the normal probe, 80% of power output and 
the pulser was set at 4 seconds for 10 minutes. It should be noted that the 
resuspended cells should keep on ice during the whole sonication process. The 
sonicatior used was supplied by Sonic & Materials, Vibra Cell. After sonication, 2 x 
100 |li1 aliquots of lysate were collected for SDS-PAGE analysis. Then, the lysate was 
split into two 50-ml centrifuge tubes and centrifuged at 15,000 rpm for 30 minutes at 
4"C. The supernatant obtained after centrifugation was added with 0.04% sodium 
azide and stored at 4"C. Next, the pellet was resuspended with 40 ml of Detergent 
Buffer (0.2 M NaCl, 1% Deoxycholic Acid and 1% NP-40) and sonicated with the 
normal probe, 80% of power output and the pulser was set at 4 seconds for 2 minutes. 
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The re-suspension was centrifuged at 5,000 rpm for 10 minutes at 4"C. Same as before, 
the supernatant was added with 0.04% sodium azide and stored at 4"C. After that, the 
pellet was resuspended with 40 ml Triton X-IOO/EDTA Buffer (1% Triton X-100 and 1 
m M EDTA). The rc-suspension was sonicated and ccntrifuged with the same 
procedures as before. The previous step was repeated two more times with the Triton 
X-100/EDTA buffer. Finally, the pellet was resuspended with "Gel Filtration 
Column" buffer plus 20 m M D T T (For HBx - 8 M Urea, 20 m M NaOAc, 150 m M 
NaCl and pH 5.4) or "Nickel Column" binding buffer (For 6xHis-HBx - 8 M Urea, 100 
m M Tris-HCl, 10 m M Imidazole, 0.5 M NaCl and pH 7.4). Sonication was also 
employed to ensure the pellet was completely dissolved. The dissolved inclusion 
bodies were then placed at 4"C and mixed end-over-end overnight. 
2.6.2 His-Tagged HBx Purification by Affinity Chromatography 
The resin - Chelating Sepharose Fast Flow (Amersham Pharmacia Biotech, Cat. No.: 
17-0575-01) - was employed to purify His-Tagged HBx proteins. It was composed of 
Iminodiacetic acid coupled to Sepharose Fast Flow for purifying proteins via metal ion 
complex formation. The resin was packed into C 16/20 column (Amersham 
Pharmacia Biotech, Cat. No.: 19-5101-01) and connected to the A K T A prime machine 
(Amersham Pharmacia Biotech). The column was then equilibrated with the binding 
buffer (8 M Urea, 100 m M Tris-HCl, 10 m M Imidazole, 0.5 M NaCl and pH 7.4) until 
the absorbance became steady. The dissolved inclusion bodies were centrifuged at 
15,000 rpm for 30 minutes at 4"C to remove any insoluble precipitates. The 
supernatant containing dissolved 6xHis-HBx was decanted carefully and then loaded 
onto the equilibrated column. Bound protein was eluted with a linear gradient 
between 10 m M to IM imidazole (Fig 3.4.1) in 300 ml of the binding buffer and the 
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elution buffer (8 M Urea, 100 m M Tris-HCl, IM Imidazole, 0.5 M NaCl and pH was 
7.4). The rate flow was adjusted to 3 ml/min throughout the experiment and the 
column was collected in 6-ml fraction. 
2.6.3 HBx Purification by Size Exclusion Chromatography 
The HBx that was expressed without fusion protein was purified by size exclusion 
chromatography. The HiLoad 26/60 Superdex 200 Prep Grade (Amersham 
Pharmacia Biotech, Cat. No.: 17-1071-01) was connected to the A K T A prime machine 
and pre-cquilibrated with 340 ml of "Gel Filtration Column" buffer (8 M Urea, 20 m M 
NaOAc, 150 m M NaCl and pH 5.4). The dissolved inclusion bodies were centrifuged 
at 15,000 rpm for 30 minutes at 4<'C to remove any insoluble precipitates. The 
supernatant containing dissolved HBx was decanted carcfully and it was then loaded 
onto the equilibrated column. The buffer flow rate was adjusted to 2.5 ml/min and 
the fraction size collected was 3 ml/tube. 
2.6.4 Refolding of HBx and His-Tagged HBx by Oxidative Dialysis 
In previous steps, both HBx and 6xHis-HBx were purified in the denatured form in 
buffer containing 8 M urea. Protein refolding was achieved by stepwise removal of 
urea through dialysis. The refolding buffer used was composed of 20 m M NaOAc, 
100 m M NaCl, 1 m M ED'l A, 3 m M GSH, 0.3 m M GSSH and pH 5.4. The solution 
of purified HBx / 6xHis-HBx was dialyzed in refolding buffer with 5.4 M urea at 4"C 
for 3 hours. Then, the protein solution was dialyzed in another refolding buffer with 
2.8 M urea at 4"C for 3 hours. Finally, the protein solution was dialyzed in refolding 
buffer at 4"C for 3 hours twice to completely remove all urea in the protein solution. 
After refolding, the soluble HBx and His-Tagged HBx were concentrated using 
Methodology 32 
Centiiprep (Millipore, Cat. No.: 4302). The procedure of dialysis refolding of HBx 
and 6xHis-HBx was summarized as a flow chart below (Fig 2.6.1): 
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20 m M NaOAc 
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1 m M E D T A 
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pH ^  
I  
Dialysis at 4"C for 3 Hours  
Fig 2.6.1 
Flow chart summarized the procedures of dialysis refolding of HBx and 6xHis-HBx 
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2.7 Purification of XIP 
2.7.1 Screening of Chromatographic Conditions for the Purification of XIP 
The Hilrap Selection kit was used to select for the appropriate ligand and experimental 
conditions for XIP purification through hydrophobic interaction chromatography. 
The HiTrap HIC Selection Kit includes five HIC media with different hydrophobic 
characteristics for small-scale media screening and selection. All five HIC media were 
prepacked in 5 X 1 ml HiTrap columns. The five prepacked HiTrap HIC columns 
included Phenyl Sepharose High Performance (1 ml), Phenyl Sepharose 6 Fast Flow 
(low sub) (1 ml), Phenyl Sepharose 6 Fast Flow (high sub) (1 ml), Butyl Sepharose 4 Fast 
Flow (1 ml), Octyl Sepharose 4 Fast Flow (1 ml). 
All the five prepacked HiTrap HIC columns were pre-equilibrated with 5 bed volumes 
of the binding buffer (50 m M PB, 1 M (NHJ^SO^and pH 7.0). The soluble fraction 
of lysate that was dialyzed overnight in the binding buffer was loaded onto each HIC 
columns. The columns were then washed with 5 bed volumes of binding buffer. 
Proteins adsorbed were then eluted with 5 bed volumes of the elution buffer (50 m M 
PB and pH 7.0). Both the wash fractions and the elution fractions were collected (1 ml 
/ Fraction) and analyzed by SDS-PAGE to see which HIC columns bind XIP. 
Methodology 35 
2.7.2 XIP r ' Step of Purification by Hydrophobic Interaction 
Chromatography 
Based on the result of HiTrap HIC Selection Kit, the HiTmp Phenyl H P 5ml 
(Amersham Pharmacia Biotech, Cat. No.: 17-5195-01) was used in the first step 
purification of XIP. Separation of XIP from other proteins was achieved by 
hydrophobic interaction chromatography (HIC). 
The HiTmp Phenyl H P column was connected to the A K T A prime machine (supplied 
by Amersham Pharmacia Biotech) and pre-equilibrated with the binding buffer (50 m M 
PB, 1 M (NH4)2S04 and pH 7.0) until the absorbance became steady. Ihe XIP 
supernatant that was dialyzed overnight in the binding buffer was loaded onto the 
HiTmp Phenyl HP column. The column was continuously washed with the binding 
buffer until the absorbance reached the baseline. The XIP was then eluted using the 
elution buffer (50 m M PB, pH 7.0) until the absorbance reached the baseline again. 
The flow rate was adjusted to 3 ml/min throughout the whole experiment. The 
column was collected in 5-ml fraction. 
2.7.3 XIP 2nd Step of Purification by Size Exclusion Chromatography 
The second step of XIP purification employed size exclusion chromatography. The 
HiLoad 26/60 Superdex 75 Prep Grade (Amersham Pharmacia Biotech, Cat. No.: 
17-1071-01) was used. 
I he HiLoad 26/60 Superdex 75 Prep Grade was connected to the A K T A prime 
machine and pre-equilibrated with 340 ml of column buffer (50 m M PB, 150 m M NaCl 
and pH 7.0). The XIP sample that was pooled from the fractions of HiTrap Phenyl 
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H P column was loaded onto the equilibrated column. The buffer flow rate was 
adjusted to 2.5 ml/min and the fraction size collected was 3 ml/tube. 
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2.8 Chemical Denaturation Experiment of HBx and XIP 
2.8.1 Preparation of Urea Buffers for the Chemical Denaturation of HBx 
For HBx chemical denaturation curve, different concentrations of urea buffers were 
prepared according to the Table 2.7.1. 
Table 2.8.1 Buffer preparation for HBx chemical denaturation experiment 
Blanks Samples  
Final [Urea] (M) 10M Urea (lal)" 10mM PB(^I)^ Vol. (nl) Final [Urea] (M) 10M Urea (nl)" 10mM PB(\i\Y HBx (ul)^ Vol. {“I) 
0.00 0,00 250.00 250 0.00 0.00 187.50 62.5 250 
0.50 12.50 237.50 250 0.50 12.50 175.00 62.5 250 
0.75 18.75 231.25 250 0.75 18.75 168.75 62.5 250 
1.00 25.00 225.00 250 1.00 25.00 162.50 62.5 250 
1.25 31.25 218.75 250 1.25 31.25 156.25 62.5 250 
1.50 37.50 212.50 250 1.50 37.50 150,00 62.5 250 
1.75 43.75 206.25 250 1.75 43.75 143.75 62,5 250 
2.00 50.00 200.00 250 2.00 50.00 137.50 62,5 250 
2.25 56,25 193.75 250 2.25 56.25 131.25 62,5 250 
2.50 62.50 187.50 250 2.50 62,50 125.00 62.5 250 
2.75 68.75 181.25 250 2.75 68.75 118.75 62.5 250 
3.00 75,00 175.00 250 3.00 75.00 112.50 62,5 250 
3.25 81,25 168,75 250 3.25 81.25 106.25 62.5 250 
3.50 87.50 162.50 250 3.50 87.50 100.00 62.5 250 
3.75 93,75 156,25 250 3.75 93.75 93.75 62.5 250 
4.00 100.00 150.00 250 4.00 100.00 87.50 62.5 250 
4.50 112.50 137.50 250 4.50 112.50 75.00 62.5 250 
5.00 125.00 125.00 250 5.00 125.00 62.50 62.5 250 
5.50 137.50 112.50 250 5.50 137.50 50.00 62.5 250 
6.00 150.00 100.00 250 6.00 150,00 37.50 62.5 250 
7.00 175.00 75.00 250 7.00 175.00 12.50 62.5 250 
7.50 187.50 62.50 250 7.50 187.50 0.00 62.5 250 
The 10 m M PB buffer used for prepamton = pH 6.5 
h 
I he 10 M Urea buffer used for preparation = pH 6.5, in 10 m M PB 
c 
The Hepatitis B Virus X Protein (HBx) = 33.44 |amole/)jl (Stock) 
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2.8.2 Preparation of Different GdnHCl buffer for the Chemical Denaturation 
of XIP 
For XIP chemical denaturation curve, different concentration of GdnHCl buffers were 
prepared according to the table below (Table 2.8.2): 
Table 2.8.1 Buffer preparation for XIP chemical denaturation experiment 
Blanks Samples  
Final [GdnHCl] (M) 8M GdnHCl (pi)'' 10mM PBI^il)" Vol. (^1) Final [GdnHCl] (M) 8M GdnHCl 10mM PB(^I)^ XIP (^l)c Vol. (nl) 
0.00 0.00 500.00 500 0.00 0.00 480.00 50 500 
1.00 62.50 437.50 500 1.00 62.50 417.50 50 500 
2.00 125.00 375.00 500 2.00 125.00 355.00 50 500 
3.00 187.50 312.50 500 3.00 187.50 292.50 50 500 
4.00 250.00 250.00 500 4.00 250.00 230.00 50 500 
5.00 312.50 187.50 500 5.00 312.50 167.50 50 500 
6.00 375.00 125.00 500 6.00 375.00 105.00 50 500 
7.00 437.50 62.50 | 500 | | 7.00 437.50 42.50 50 500 
a 
The 10 m M PB buffer used for preparaton 二 pH 7.0 
h The 8 M GdnHCl used for preparation = pH 7.0, m 10 m M PB 
c . 
The Hepatitis B Virus X Interacting Protein (XIP) = 400 |imole/|al 
Methodology 39 
2.8.3 Calculation for Chemical Denaturation Experiment 
2.8.3.1 Protein Concentration Calculation 
Protein concentration of a sample in a particular unit (|aM or mg/ml) was required for 
prediction of its secondary structure and subsequent for calculation of its chemical 
unfolding data. The absorbance (A) was related to the light intensity before (Jo) and 
after (7) passage through the protein solution. The concentration of a protein sample 
was calculated as follows: 
A = - loglO {I/Io) 
A - ex fX / 
A = £ X (mole/volume) x / 
A = 8 X (mass/molar mass/volume) x / 
Concentration of a protein sample (|iM) = A / 8 / / x 10^ ' 
Concentration of a protein sample (mg/ml) = A / s / / x molar mass x 10'、 
where c is the molar concentration, / is the path length in cm and s is the molar 
absorbance coefficient 
2.8.3.2 Residual Molar Ellipticity Calculation 
® 、 
The data recorded by the Jasco J 810 Spectropolariincter were in the form of ellipticity 
in millidegree. The data in the millidegree format could be converted to a standard 
unit - Residual Molar Ellipticity (RME). It was based on the concentration of the sum 
of the amino acids in the protein solution under investigation. So, it was ideal for 
batch-to-batch experiment comparison and for subsequent calculations. Below was 
the equation for Residual Molar Ellipticity (RME) calculaition: 
RMj^’ 二 Ellipticity (CD signal) x 100 x Molecular Weight (M,.)  
“ Concentration (c) x light path (1) x Number of amino acid residue 
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2.8.3.3 Free Energy Change (AGJ Calculation 
The chemical denaturation experiment was performed to determine AGyCHjO)，which 
could directly reflect the conformation stability of a protein. In the chemical 
unfolding experiment of HBx, protein sample was dissolved in 10 m M PB, pH 6.5 with 
different concentration of urea at 25°C making the final concentration of protein about 
8.36 |LIM. The concentration of urea ranged from 0.0 - 7.5 M with 0.5 M interval 
(Table 2.8.1). The protein sample of 200 j^l was loaded in the sample cell with light 
path 0.05 cm and incubated at 25°C for 5 minutes. During chemical denaturation, 
protein was changed from the folded state to unfolded state in the presence of 
denaturant. 
Folded (F) ， 、 Unfolded (V) 
As f|, and f^- represented the fraction protein present in the folded and unfolded 
conformations respectively, f,； + f"「二 1. (Pjice and Scholtz, 1997). Then, the 
equilibrium constant K and the free energy change, AG, could be calculated using: 
K = FL, / f, = f；. / (1- y and A G = -RT In K 
where R is the gas constant (8.314 J mol ' K') and T is the absolute temperature (K), 
298K (25。C) 
After getting the fraction unfolded, the chemical denaturation curve could be plotted 
and the AG^, at the transition state could be calculated using the above formula. 
AGU(H2()) could be determined by plotting the AG。in the transition state against 
denaturant concentration, |D]. Since AG^,(H20) represented the free energy of protein 
in the absence of denaturant, this data can be obtained by extrapolation of the curve to 
y-axis in the curve ACj^ ,(H20) against [Dj. [D],/2was the concentration of denaturant 
(GdnHCl) at which the protein was half-folded. 
Methodology 41 
2.9 Two-dimensional Hetetonuclear Nuclear Magnetic Resonance (NMR) 
Experiment 
'^ N labeled XIP sample for the 2D heteronuclear N M R Experiment was obtained by 
expressing the protein in M 9 medium (Appendix VO) supplemented with '^NH^Cl as 
the sole nitrogen source. The XIP was purified by HiTrap Phenyl HP 5 ml Column 
and HiLoad 26/60 Superdex 75 Prep Grade Column as described before (Section 2.4.3). 
The purified protein was concentrated to 1 m M in 150 m M NaCl, 50 m M sodium 
phosphate buffer at pH 7.0. A heteronuclear single quantum correlation 
(HSQC) experiment was acquired at 298K on a bruker M I X SOOMHz N M R 
spectrometer at the Department of Chemistry, the Chinese University of Hong Kong. 
The spectral widths on the 'H and '^ N dimensions were 5556 and 1267 Hz, respectively. 
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2.10 Interaction Confirmation between HBx and XIP 
2.10.1 Transfection of pEGFP, pEGFP-HBx and pEGFP-XIP into HepG2 
The transfection of HepG2 liver cells was performed according to the guidelines 
fecommended by the protocol provided with the LipofecL\MINE ‘ Reagent. The 
concentrations of D N A and LipofectAMINE""' Reagent, PLUS Reagent, cell density 
and transfection times in the transfection protocols were adjusted in proportion to the 
change in culture dish surface area. 
The day before transfection, around 1.1-3.3 X 10^  cells was seeded per well in a 6-well 
plate in 3 ml of the appropriate complete growth medium (with serum as our HepG2 
cells are normally cultured in the presence of serum). The cells were incubated at 
37"C in a C()2 incubator until the cells were 50-80% confluent. This step would 
usually take 18-24 hours. When the cells were ready, the cells were transfected with 
our recombinant fluorescent protein plasmids. Before beginning transfected, the 
plasmids were pre-complexed with PLUS Reagent (Invitrogen, Cat. No.: 11514-015). 
l-2|ig D N A was diluted into 100 \x\ dilution medium without serum (Dulbecco's 
Modified Eagle Medium (D-MEM))，then 6|al Plus Reagent was added to the diluted 
D N A and was mixed. The D N A Plus mixture was incubated at room temperature for 
15 min. During the D N A Plus mixture incubation time, diluted lipofectAMINR"^' 
was prepared as follows: 4^1 of LipofectAMINE™ Reagent was diluted into 100 jji 1 
medium without serum in a second tube, mixed and incubated at room temperature for 
15 min. After incubation, the pre-complexed D N A and diluted IipofecL\MlNE'^' 
Reagent were combined, mixed gently, and incubated at room temperature for 15 min 
more to allow DNA-liposomc complexes to form. While complexes were forming, 
the cells were washed with Ix PBS and the medium on the cells was replaced with 0.8 
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ml of transfection medium without serum (D-MEM without serum). Next, for each 
transfection, the DNA-PLUS-LipofectAMINE'M Reagent complexes were added to 
each well of cells containing fresh medium. The complexes were mixed into the 
medium gently and the cells were incubated at 37"C at 5% CO, for 3 hours. After 3 
hours incubation, in order to maximize cell growth, the medium containing the 
complexes was replaced with 3 ml fresh, complete medium. Finally, the cells were 
allowed to recover from transfection and were incubated for 18-24 hours at 37"C in a 
CO2 incubator. Then, the cells (with transfection of different plasmids) that seeded on 
the slips were collected, fixed by 3.7% formaldehyde and mounted on slides using 30% 
glycerol. The confocal microscope and the Leica TCS software were used for data 
collection and the gene expression of the transfected plasmids was examined. 
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2.10.2 Yeast Two-Hybrid System for Confirmation of HBx and XIP 
Interaction 
2.10.2.1 Prepatation of Y187 Competent Cells (Small Scale) 
1 ml of Y P D A (Appendix IX) was inoculated with several 2-3 m m colonies and it was 
vortexed vigorously to disperse any clumps. Then, the cells were transferred to a flask 
containing 50 ml of YPDA. The yeast culture was incubated at 30()C for 16-18 hours 
with shaking (250 rpm) to stationary phase (OD。"" > 1.5). After that, the overnight 
culture was transferred into 300 ml of Y P D A to produce an O D _ 二 0.2 ~ 0.3 yeast 
culture. The yeast competent cell culture was incubated at 3()"C for 〜3 hours with 
shaking (250 rpm) until OD。",, 二 0.4 〜（)/). Next, the cells were placed in 300 ml 
centrifuge bottle and centrifuged at 1,000 x g for 12 minutes at 2()"C. The supernatant 
was discarded and the ccll pellet was resuspended by vortexing in 50 ml of sterile H,0. 
The cells were centrifuged again at 1,000 x g for 12 minutes at 2()"C. Same as before, 
the supernatant was discarded and the cell pellet was resuspended with 1.5 ml freshly 
prepared and sterile IX TE/LiAc. Finally, aliquots of yeast competent cells (100 ⑷ 
was made into sterile 1.5-ml inicrofuge tubes for yeast transformation. 
Methodology 45 
2.10.2.2 Trans format ion of p G B K T 7 - H B x and p A C T 2 - X I P into Y187 (Small Scale) 
Firstly, the PEG/LiAc solution (8 ml 50% P E G Stock, 1 ml lOX T E Stock and 1 ml 
】jiAc Stock, See Appendix X for preparation of Stock Solutions) was prepared, which 
was required for yeast tmnsformation. Then, in the labeled aliquots (Positive, Negative, 
1, 2 & 3) of competent cells, the following components were added and mixed: 
Samples Construct DNA BP (0.1 /zg) Construct AD (0.1 " g ) Herring Tests Carrier DNA (0.1 mg) 
Positive pVA3-1 pTD1-1 V 
Negative pGBKT7 pACT2 V 
1 pGBKT7-HBx pACT2 yj 
2 pGBKT7 pACT2 - XIP V 
3 pGBKT7 - HBx pACT2 - XIP V 
The mixture of D N A and yeast cells was mixed well by vortexing. Next, 0.6 ml of 
sterile PEG/LiAc solution was added and vortexed at high speed to mix. The 
transformation mixture was incubated at 3()"C for 30 minutes with shaking (200 rpm). 
After incubation, D M S O (70 |al) was added and mixed well by gently inversion or 
swirling. The mixture was then heat shocked for 15 minutes in a 42"C water bath. 
After heat shock process, the cells were chilled on ice for 2 minutes. The cells were 
then centrifuged at 14,000 rpm for 5 seconds at room temperature. Finally, the 
supernatant was removed, the cells were resuspended in 0.2 ml of IX T E and was 
spreaded onto SD/-I.cu/-Tfp plates. 
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2.10.2.3 P-galactosidase Colony Lift Assay 
The Z Buffer stock solution, X-Gal stock solution and the Z Buffer/X-Gal solution 
were prepared as follow: 
Na2HP〇4 • 7H2〇 16.1g/L 
Na2HP04 • 7H2〇 5.5g/L 
Z Buffer Stock Solution KCl 0.75g/L 
MgS〇4 • 7H2〇 0.246g/L 
Adjust pH to 7.0; Autoclave; Store for 1 year 
X-Gal Stock Solution 20 mg/ml; Wrap by foil, Store in dark at -20oC 
Z Buffer (Stock) 100ml 
Z Buffer / X-Gal Solution X-Gal (Stock) 1.67ml 
p-Mercaptoethanol 0.27ml 
Freshly prepared colonies and Z buffer/ X-gal solution should be used and sterile filter 
paper was presoaked in 1.5 ml Z buffer/ X-gal solution in 90-mm Petri dish. Another 
clean filter paper was placed to rub colonies onto the plate and the orientation of the 
paper was marked by needle. The rubbed filter paper with colonies was placcd to a 
pool of liquid nitrogen to submerge for about 10 seconds. The filter paper was then 
allowed to thaw at room temperature and the paper was placcd with colonies side up on 
presoaked filter paper and trapping of bubbles should be avoided. The filter paper 
was then incubated at 30"C and the appearance of blue color was checked from 30 
minutes to 8 hours. Colonies with blue color after more than 8 hours of incubation 
should be regarded as false positives. 
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Expression, Purification and Characterization 
Chapter 3 
of Hepatitis B Virus X Protein (HBx) 
3.1 Introduction 
The Hepatitis B Virus (HBV) has been implicated in many serious liver diseases such as 
liver cirrhosis and hepatocellular carcinoma (HCC). The genome of H B V carries four 
open reading frames (ORFs) that encode the core antigen, the surface antigen, the D N A 
polymerase and the HBx protein. The HBx is a multifunctional protein, which is 
believed to be the determinant that leads to hepatocellular carcinoma in chronic H B V 
infected patients. However, the molecular basis of HBx functions, its transactivation 
properties and its role in hepatocarcinogenesis has not been fully understood. The 
pre-requisite of structure-function studies of HBx is to express and purify HBx proteins. 
However, in previous studies, HBx proteins expressed as intracellular aggregates in both 
baculovirus (Urban et aL, 1997) and prokaryotic expression systems (Chisaka et aL, 1987; 
Gupta et aL, 1995; Marczinovits et aL, 1997; Rui et aL, 2001). Different methods have 
been reported for purification and refolding of HBx proteins from its insoluble form, 
but all HBx proteins either expressed as fusion proteins or truncated variants or 
synthetic peptides that corresponding to certain parts of the X gene (Chisaka et aL, 
1987). For example, HBx was expressed in fusion with glutathione-S—transferase 
(GSl) (Marczinovits et aL, 1997; Rui et aL, 2001) or in fusion with a six-histidine tag 
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(6xHis) (Urban et al., 1997; Rui et al�2001). Moreover, none of their studies have used 
biophysical methods to characterize the structure and the stability of HBx to see if the 
refolded protein adopts a stable conformation. In this chapter, the focus is on the 
purification and the refolding of the full length non-fused, non-truncated HBx protein 
and its structural characterization. 
3.2 Construction of Recombinant HBx-pRSETA and 6xHis-HBx-pRSETA 
Plasmids 
The D N A fragment encoding the full length of HBx protein was amplified by PGR and 
directionally cloned into the bacterial expression vectors pRSETA and 6xHis-pRSETA 
(modified based on pRSETA from Invitrogen) via Bglll and EcoRI restriction sites. 
The vectors pRSETA and 6xHis-pRSETA have BamHI and EcoRI restriction sites 
(Bglll and BamHI are compatible, refers to Methodology, section 2.3.1), which allow 
the directional insertion of a D N A sequence to be expressed under the control of a T7 
promoter. A start codon A T G and Gly Ser amino acids residues (due to the BamHI 
restriction sites) are located upstream of the insertion site in the case of pRSETA. 
While a six-histidine tag encoding sequence and a thrombin cleavage site are located 
upstream of the insertion site in the case of 6xHis-pRSETA. For the two HBx 
constructions (HBx-pRSETA and 6xHis-HBx-pRSETA), the following oligonucleotides 
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were used: sense [5'-TAGGGCAGATCTGCTGCTCGGATGTGCTGCAAACTG-3'] and 
anti-sense [5'-TAGGGCGAATTCTTAGGCAGAGGTGAAAAAGTTGCATGG-3']. For the 
PGR amplification, 30 cycles consisting of the following steps were used: 94"C (30 sec), 
58"C (30 sec), 72"C (1 min) (Fig 3.2.1). Amplified PGR products were digested with 
Bglll and EcoRI while pRSETA and 6xHis pRSETA were digested with BamHI and 
EcoRI (Fig 3.2.2). Then, digested PGR products were ligated into pRSETA and 6xHis 
pRSETA respectively. D H 5 a E. coli cells were transformed with the recombinant 
vectors. Recombinant plasmid D N A isolated from the D H 5 a was analyzed by PGR, 
enzyme digestion and 1.25% agarose gel electrophoresis (Fig 3.2.3). By comparing the 
size of the PGR and enzyme digestion products, HBx was successfully cloned into 
pRSETA and 6xHis pRSETA. Finally, the HBx-pRSETA and 6xHis-HBx-pRSETA 
clones were confirmed by D N A sequencing (Service Team of Department of 
Biochemistry, CUHK). 
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Fig 3.2.1 - HBx PGR products for cloning of HBx into pRSETA and 6xHis-pRSETA 
Lane M - X Hind III Marker, Lane 1 - Template DNA used in the PGR reaction and Lane 2 
-HBx PGR Products. 
_ 
Fig 3.2.2 • Restriction digestions of HBx PGR Products, pRSETA and 6xHis-pRSETA 
Lane M - X Hind III Marker, Lane 1 & 2 - HBx PGR Products digested by Bglll and EcoRI, 
Lane 3 - Uncut pRSETA, Lane 4 - pRSETA digested by BamHI and EcoRI, Lane 5 -
Uncut 6xHis-pRSETA and Lane 6 - 6xHis-pRSETA digested by BamHI and EcoRI. 
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Fig 3.2.3 - Screening of transformed clones by restriction digestion 
(Cloning of HBx into pRSETA and 6xHis-pRSETA) 
Lane M - X Hind III Marker, Lane 1 - 6xHis-HBx pRSETA clone and Lane 2 & 
3 - HBx-pRSETA clones. DNA fragments of size 0.47kb was cut out using 
BamHI and EcoRI in all three clones. This implies that HBx was 
successfully cloned into pRSETA and 6xHis-pRSETA. 
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Fig 3.2.4 • Screening of transformed clones by PGR 
(Cloning of HBx into pRSETA and 6xHis-pRSETA) 
Lane M - X Hind III Marker, Lane 1 - 6xHis-HBx pRSETA clone 
and Lane 2 & 3 - HBx-pRSETA clones. D N A fragments of 
size 0.47kb was amplified in all three clones. This implies 
that HBx was successfully cloned into pRSETA and 
6xHis-pRSETA. 
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3.3 Expression of 6xHis-HBx in E. coll C41 (DE3) using M9ZB Medium 
E. coli Strain C41 (DE3) was used for protein expression because the basal level of 
expression of proteins encoded in pET and related vectors was low, where as the 
expression of the target gene could be strongly induced. Also, this strain would 
continue to grow in most of the cases after addition of IPTG, so that induction of 
expression can be continued over a long period (Miroux B. et al, 1996). The 
recombinant 6xHis-HBx-pRSETA plasmid D N A was transformed into E. coli C41 
(DE3), which was then grown in M 9 Z B medium containing ampicillin (100|lg/ml) to an 
()1)6丨丨丨丨=0.4 〜1.0, followed by addition of isopropylthio-p-D-galactoside (IPTG) to a 
final concentration of 0.4 m M and induced overnight at 37"C. Cells were harvested by 
centrifugation and lysed by sonication. Aliquots of 30 bacterial lysate were collected 
and analyzed by a 15% SDS-PAGE (Fig 3.3.1). The remaining bacterial lysate was 
separated in soluble and insoluble fractions by centrifugation at 13,000 x g for 30 min at 
4"C. The result of SDS-PAGE showed that all 6xHis-HBx was expressed as inclusion 
bodies. Different conditions were then tried to see if 6x-HBx could be expressed in 
soluble form. For example, different temperatures, IP TG concentration, cell strains, 
expression time and culture media were tested (Table 3.3.1). In all cases, 6xHis-HBx 
was expressed solely as inclusion bodies. 
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Expression Conditions Modification Parameters  
Temperature 25°C’ 28°C, 30°C 
IPTG Concentration (Final) 0.05mM, 0.1 mM, 0.2mM 
Different Cell Strains DH5 a, BL21 pLysS，BL21 pLysE, C41 (DE3), C43(DE3) 
Expression Time 4 Hours, 10 Hours, 20 Hours 
Different Media M9ZB, M9  
Table 3.3.1 • Different conditions tried for 6xHis-HBx expression 
Different temperatures, IPTG concentrations, cell strains, different 
expression time and medium types were tried for 6xHis-HBx 
expression. However, the formation of HBx intracellular aggregates 
still persisted. 
kDa M 1 2 3 4 5 
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Fig 3.3.1 - Analysis of the 6xHis-HBx expression and its bacterial lysate 
Lane M - Low Molecular Weight Marker, Lane 1 - Bacterial culture before 
addition of IPTG, Lane 2 - Bacterial culture after overnight-induced protein 
expression, Lane 3 - Whole lysate of 6xHis-HBx, Lane 4 - Supernatant of the 
lysate of 6xHis-HBx and Lane 5 - Pellet of the lysate of 6x His-HBx. 
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3.4 Expression of HBx in E. coJi C41 (DE3) using M9ZB Medium 
Expression of non-fusion version of HBx was similar to that of the 6xHis-HBx. The 
recombinant HBx-pRSETA plasmid D N A was transformed into E. coli C41 (DE3) for 
the expression of the HBx protein. The E. coli C41 (DE3) transformed with the 
HBx-pRSETA was grown in M 9 Z B medium containing ampicillin (100|ig/ml) to an 
OI)(,…=0.4 ~ 1.0, followed by addition of isopropylthio-P-D-galactoside (IPTG) to a 
final concentration of 0.4 m M and induced overnight at 37"C. Cells were harvested by 
centrifugation and lysed by sonication. Aliquots of 30|LI1 bacterial lysate were collected 
and analyzed by a 15% SDS-PAGE (Fig 3.4.1 & Fig 3.4.2). The remaining bacterial 
lysate was separated in soluble and insoluble fractions by centrifugation at 13,000 x g for 
30 min at 4"C. Similar to 6xHis-HBx, HBx was expressed solely as inclusion bodies 
(Hg 3.4.2). Different conditions were tried (Table 3.3.1) and formation of inclusion 
bodies persists in all cases. Subsequent efforts were then made to purify and refold the 
insoluble 6xHis-HBx and HBx. 
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Fig 3.4.1 • Analysis of the HBx expression in E. coli C41 (DE3) 
Lane M - Low Molecular Weight Marker, Lane 1 & 3 • Bacterial culture 
before addition of IPTG, Lanes 2 & 4 - Bacterial culture after protein 
expression. An additional band of size around 17kDa was found in the 
bacterial culture after overnight-induced HBx expression. So, HBx was 
expressed in the provided system successfully. 
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Fig 3.4.2 
Analysis of the HBx bacterial lysate, the fractions collected from washing of the 
HBx inclusion bodies and the HBx solubilized in gel filtration column buffer 
Lane M - Low Molecular Weight Marker, Lane 1 - Whole lysate of HBx, Lane 2 -
Supernatant of the lysate of HBx, Lane 3 - Pellet of the lysate of HBx, Lane 4 - Wash 
fraction of detergent buffer, Lane 5 & 6 - Wash fractions of Triton X-100/EDTA buffer 
and Lane 7 - Washed HBx solubilized in Gel Filtration Column buffer (8M Urea, 
20mM NaOAc, 150mM NaCI, pH 5.4). 
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3.5 Purification and Refolding of 6xHis-HBx Fusion Proteins 
A bacterial pellet derived from a IL culture induced as described in Section 3.3 was 
lysed by sonication. After centrifugation, the pellet containing the 6xHis-HBx 
inclusion bodies was washed by detergent buffer and Triton X-IOO/EDTA buffer to 
remove membrane bound proteins and lipids. The washed pellet was solubilized in a 
solution of 8 M Urea, 100 m M Tris-HCl, 10 m M Imidazole, 0.5 M NaCl and pH 7.4. 
The resulting solution was mixed end-to-end overnight to ensure complete 
solubilization of the inclusion bodies. The solution was applied to a Ni-Chelating 
Sepharose Fast Flow Column (Amersham Pharmacia Biotech, Cat. No.: 17-0575-01). 
The bound protein was eluted with a linear imidazole gradient of 10 m M to 1 M (Fig 
3.5.1). Fractions collected were analyzed by 15% SDS-PAGE (Fig 3.5.2). From the 
gd’ the 6xHis-HBx was eluted at around 0.3 M imidazole. Refolding of 6xHis-HBx 
was achieved by progressive removal of urea. Peak fractions containing 6xHis-HBx 
was pooled and dialyzed against the sets of refolding buffers (refers to Methodology, 
section 2.6.4) at 4()C. The refolded protein was cleared by centrifugation at 13,000 x g 
for 30 min at 4"C to remove any precipitates formed during dialysis refolding. 
Unfortunately, the refolded 6xHis-HBx was not stable at room temperature and its 
precipitated out when concentration was greater than 0.4 mg/ml. The purity of the 
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protein was just 62% (Fig 3.5.3). It should be noted that the purity of 6xHis-HBx was 
very low and this quality of protein was not suitable for structural analysis. Actually, 
we had make an attempt to further purify 6xHis-HBx prior to its refolding, for example, 
SP Sepharose High Performance (Amersham Pharmacia Biotech, Cat. No.: 17-1087-04). 
Nevertheless, no improvement of the purity of 6xHis-HBx was observed. In the next 
section，a different strategy was developed to purify HBx from the inclusion bodies. 
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Fig 3.5.1 - Elution profile of 6xHis-HBx using Chelating Sepharose Fast Flow column 
The binding buffer was 8 M Urea, 100 m M Tris-HCl, 10mM Imidazole, 0.5 M NaCl, pH 7.4 
while the elution buffer was 8 M Urea, 100 m M Tris-HCl, 1M Imidazole, 0.5 M NaCl, pH 7.4. 
The flow rate was 3ml/min. The gradient length and gradient target were 300 ml and 100 
% B respectively. From the results of SDS-PAGE, the 6xHis-HBx was eluted at around 
0.3 M Imidazole or 30% (18 % - 50。/。）of 日ution Buffer. 
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Fig 3 . 5 . 2 -
Purification of 6xHis-HBx using Chelating Sepharose 
Fast Flow column analyzed on 15 % SDS-PAGE 
Lane M - Low Molecular Weight Marker, Lane 1 - Input 
6xHis-HBx, Lane 2 - Column flow through, Lane 3 to Lane 
11 - Fractions collected (Fraction 9 to 25) from imidazole 
gradient elution. 
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Fig 3.5.3 • 6xHis-HBx was concentrated progressively 
The refolded 6xHis-HBx was concentrated using Centriprep. 
Lane M - Low Molecular Weight Marker. The 6xHis-HBx 
proteins were stable at room temperature at concentration of 
0.28 mg/ml (Lane 1) & 0.35 mg/ml (Lane 2). However, 
6xHis-HBx precipitated out immediately at room temperature 
when concentration reached 0.5 mg/ml (Lane 3) or higher 
(Lane 4’ 6xHis-HBx = 1.4 mg/ml). 
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3.6 Purification and Refolding of HBx Proteins 
Similar to procedures used for 6xHis-HBx, inclusion bodies of HBx was washed (see 
Methodology, section 2.6.1) to remove membrane bound proteins and lipids. The 
washed pellet was solubilii^ ed in column buffer (8 M Urea, 20 m M NaOAc, 150 m M 
NaCl and pH 5.4) with additional of 20 m M DTT. Here gel-filtration was used to 
purify HBx. The solution was injected into HiLoad 26/60 Superdex 200 Prep Grade 
Column (Amersham Pharmacia Biotech, Cat. No.: 17-1071-01) that was pre-equilibrated 
with column buffer. The HBx protein and other contaminants were separated 
according to differences in their sizes as they pass through the column (Fig 3.6.1). The 
column was collected in 3-ml fraction and 10 |il aliquots were analyzed by 15% 
SDS-PAGE (Fig 3.6.2 & Fig 3.6.3). From the gel, the protein was eluted at two 
different positions: the first peak was eluted at 121 ml buffer volume while the second 
peak was eluted at 188 ml of the buffer volume. HBx eluted as two peaks suggests 
that it existed in two populations. The first peak was eluted near the void volume of 
the column, suggesting that HBx proteins were either multimeric aggregates, or bound 
to other high molecular weight protein contaminants. Being co-eluted with other small 
proteins, the second peak should correspond to HBx in monomeric form. HBx from 
both peaks were collected separately and were refolded using stepwise dialysis (refer to 
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Methodology, section 2.6.4) at 4"C. After refolding, only HBx from the second peak 
was soluble while HBx from the first peak failed to refold properly and was precipitated 
out when urea was completely removed. The refolded soluble proteins were cleared by 
centrifugation and concentrated by Centriprep (Fig 3.6.4) for subsequent circular 
dichroism (CD) analysis (see Result, section 3.7). As judged by SDS-PAGE, the purity 
of HBx was >90%. Typical yield of HBx was 20 mg per liter culture of E. coli. 
Removal of high molecular weight HBx aggregates by size exclusion chromatography 
pnoi- to refolding resulted in a much better behaved protein sample of HBx. 
Comparing to the 6xHis-HBx, HBx purified this way was much more stable at room 
temperature and it remained soluble at concentration of 2mg/mL In contrast, affinity 
chromatography used in the previous section may not be able to remove the high 
molecular weight HBx aggregates, which may be troublesome during refolding and 
cause stability problem after refolding. 
61 
XIP Expression, Purification and Characterization 101 
I I I ]——I— j- • - ± I t i 1 I t _ 
C o n d u c t i v i t y J 二 二 l ^ t P e a k o f H B x E l u t i o n — 
Absorbance j I / : 
- .——• —- • •• • • ；^^  ^^ 
Z "~：“— 
,_.,. .. • — - — -— -- - • - - - • • - — 
—.> — .―一—. . •- - - 一 . . - 4 — .. ^ ^ 
• - I , ,• J in . - • -• ” ‘ - . . - - . • - ‘ ‘~ 
一.’ . — T 
_ •一一‘‘ „. ,,„ ,.•.•_- — . . 一 — . — •— - -
,,.,..—• • -- — — — - — j ^ 
— 一 .. .. ------ - • • • ‘ — “ 
. - - - --. 一 •. — 如 一 一 •• •‘ 
^ ― ：：- — 
,一-.— — -—‘• ——• —— - • • —...... - ‘ 
— • - ‘. . . -• -..寸-‘.• 
— 一 ― — - - - . - — • — — - • « • - . - + • - - . - - - • ” • • - -— •—— n -.-... * 
4 • r \ — 1 ？A ‘ •-- 一-J - - - i-Ul  
一— rrc — • - ‘ I …. ——— “ - —‘"‘ 1 
z z i i z i E j ^ i z =—::—,. 1：! i ] f ： ： ： 二 — — — 二： 
— —…^ — •一\ i — 二：食4—t—— ——-i;i i ；：：： ‘ 
f ^ i 1 f-^  -
TO ' V " -t—— — — — 
_- . W . L — - A - - - - — 
- TJ. - _ - • .4 Xi -- ---- - — - - . - — ^ 
.. 一，; /| - . . _ —一 . ^  1 
- \ \ .--. ‘ 
/ .J —. , < .-iV I irt l-l I ‘ • ^ I 
—4. i M l t U -— 9 -V   
• , I : . J1. •； H.t, . � . . t • 
‘ • . • , 1 - • T • • 
.-_ 一 — . . -• —十，J- - • .十—— • -F 7 
— P e a k o f HBx Elution : : : : 
. • … • 丨 —-— - . . -— 
- • __ -. — - • - — _ .._ - * 
. — J . — — E ： — — — I & - J — — — — — ^ — 
Fig 3.6.1 • Elution profile of HBx using HiLoad 26/60 Superdex 200 Prep Grade column 
The column buffer was 8 M Urea, 20 m M NaOAc, 150 m M NaCI and pH 5.4. The flow rate 
was 2.5 ml/min. The fraction size was 3 ml/tube. Two peaks were found from the graph. 
From the results of SDS-PAGE, the HBx was eluted as two different batches - The 1st peak of 
HBx was eluted at around 121 ml buffer volume and eluted together with lots of high molecular 
weight proteins; the peak of HBx was eluted at around 188 ml (175 ml to 202 ml) buffer 
volume of very high purity. 
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Fig 3.6.2 
Purification of HBx (1st Peak) using HiLoad 26/60 Superdex 
200 column analyzed on 15 % SDS-PAGE 
This SDS-PAGE referred to the 1st peak of HBx eluted from the 
column. Lane M - Low Molecular Weight Marker, Lane 1 - HBx 
protein injected into the column and Lane 2, 3, 4, 5, 6, 7, 8, 9 & 
10 - Fraction 1，4, 7，10, 13, 16, 19，22 & 25 collected from the 
column. As showed from the gel, HBx bound to lots of high 
molecular weight proteins and these contaminants might cause 
troublesome during refolding and stability at room temperature. 
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Purification of HBx (2"^ Peak) using HiLoad 26/60 Superdex 200 
column analyzed on 15 % SDS-PAGE 
This SDS-PAGE referred to the peak of HBx eluted from the 
column. Lane M - Low Molecular Weight Marker, Lane 1 - HBx 
protein injected into the column and Lane 2’ 3，4, 5, 6, 7, 8, 9 & 10 -
Fraction 28，31, 34, 37,40,43,46,49 & 52 collected from the column. 
As showed from the gel, this batch of HBx was much more pure than 
the first batch. All fractions of the peak fractions were pooled and 
concentrated using Centriprep. 
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Fig 3.6.4 - HBx was purified and concentrated using centriprep 
Lane M - Low Molecular Weight Marker. When compared to the input 
HBx sample (Lane 1) for the column, after HiLoad 25/60 Superdex 200 
column purification, the HBx was highly purified (Lane 2). This 
quality of HBx sample, the concentration was 1.8 mg/ml and its purity 
was around 90%, could be used for structural studies such as circular 
dichroism spectrum measurement for secondary structure prediction. 
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3.7 Structural Characterization of Refolded HBx 
3.7.1 Introduction 
All chiral compounds, including proteins, exhibit a preference for the absorption of 
either left or right circularly polarized light. This phenomenon results in circular 
dichroism (CD). Because the C D spectra for polypeptides in the a helix, p sheet and 
random coil conformations are very different, so circular dichrosim can be a powerful 
tool for following conformational changes in proteins under different conditions. For 
example, C D can be used to monitor the structural changes upon denaturation by pH or 
denatumnt. It can also be used to estimate the relative amount of secondary structure 
elements. Because the contributions of different secondary structures to the circular 
dichroism at different wavelengths are known, so comparative samples are available to 
imtch an observed spectrum for a protein by a combination of such contributions. 
The C D signals of proteins occur in two spectral regions. The peptide bonds 
contribute to the absorbance in the far-UV or amide region (170-250 nm) while the 
aromatic amino acids contribute to the signal in the near-UV region (250-300 nm). 
The two spectral regions give different kinds of information about the protein structure. 
For example, the a helix displays a strong and characteristics C D spectrum in the 
far-UV region — prominent and negative bands are observed at 222 n m and 208 nm. 
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3.7.2 Experimental Analysis of HBx Secondary Structure 
C D analysis was applied to find out the relative amount of secondary structure 
components (a helix, p sheet and random coils) of the refolded HBx. The C D 
spectrum of HBx was measured at 25"C, 10 m M PB at pH 6.5 was used as blank. The 
spectrum showed a dominant negative peak at 208 nm and a strong negative C D signal 
at around 222 nm (Fig 3.7.1), suggesting that the HBx contains a helixes in its 
secondary structure. The table below showed the content of secondary structures in 
refolded HBx estimated from its C D spectrum by the program C D N N : 
Secondary Structure Elements ~Refolded HBx Experimental Structural Prediction 
g Helix 30.5% 
P Sheet 19% 
Turns I Coil 48.5% 
Total Sum 98%a 
“Due to errors in protein concentration estimation and in fitting of secondary structural elements, total 
sum reported by the CDNN program will only be dose to but not equal to 100%. 
6 6 
fi7 
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Fig 3.7.1 • HBx Circular Dichroism Spectrum In 10 mM PB, pH 6.5 
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Fig 3.7.1 - HBx circular dichroism spectrum in 10 mM PB, pH 6.5 
The spectrum obtained showed two dominant negative peaks at 222 nm and 208 
nm. This implied that the HBx contained a helixes in its secondary structure. 
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3.7.3 Chemical Denaturation Experiment of HBx 
Having a good C D spectrum is only one of the criteria for a successfully refolded 
protein. To see if the refolded HBx adopts a stable conformation, the free energy of 
denaturation of HBx was measured by chemical denaturation experiment. HBx was 
mixed with different concentration of denaturant (urea), and the percentage of 
denaturated HBx was followed by C D signal at 222 nm. The chemical denaturation 
curve of HBx showed a two-state transition, suggesting the HBx adopts a stable 
conformation that denatures cooperatively (Fig 3.7.2). In increasing concentration of 
urea, the proportion of denaturated HBx increased (Fig 3.7.3). The mid-point and the 
slope (m-value) of the transition were 2.8 M and 4.8 k|/(moLM), respectively. The 
stability of HBx, measured by the free energy of denaturation was 2.8M x 4.8 kj/ (mol 
M) = 13 kj/mol. 
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Fig 3.7.2 - HBx Chemical Denaturadon Curve 
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Fig 3.7.2 - HBx chemical denaturation curve 
Fraction unfolded of HBx was plotted against Urea Concentration. It 
was observed that the mid-point of HBx transition (from folded state to 
unfolded state) was 2.8 M urea and the m-value was 4.8 kJ/(mol M). 
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Fig 3.7.3 - Comparison of CD Spectra of HBx in different concentration of Urea 
The CD spectra of HBx in OM Urea (blue), 3.75M Urea (pink) and 7.5M Urea (green) 
was shown. The decreasing negative signals at 222nm were observed with 
increasing concentration of urea. The CD spectra below 210 nm are unreliable for 
protein samples containing urea, which interferes with C D measurements. 
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3.8 Discussion 
In many previous studies, HBx proteins were either expressed in a truncated form or in 
fusion with glutathione-S-transferase (GSl^ or six-histidine tag (6xHis). HBx was 
always expressed as an insoluble form and itself was not stable at room temperature. 
Linkage with different fusion parts, therefore, might ease purification of HBx. For 
example, 6xHis-HBx could be purified by Ni-Chelating Sepharose Fast Flow column in 
a single step. Nevertheless, the structure of HBx protein was not characterized m any 
of these studies. In our laboratory, we also worked on two different constructs of 
HBx - one was fused with a six-histidine tag and the other was expressed without 
fusion. Two types of HBx were purified by different chromatographic methods 
followed by refolding of the expressed proteins. Ultimately, the non-fusion version of 
HBx was characterized. It is because we could overcome two major problems faced 
during the purification and the refolding procedures - the purity of the HBx protein 
and its stability at room temperature. In the following part, how we solved the 
problems was discussed. 
70 
XIP Expression, Purification and Characterization 101 
3.8.1 HBx was Expressed, Purified and Characterized instead of 6xHis-HBx 
The first thing was that HBx was expressed, purified and characterized instead of 
6xHis-HBx. Although both types of HBx were purified and refolded, the results 
suggested that HBx was a much better behaved protein sample when compared with the 
6xHis-HBx, which tended to precipitate out when urea was completely removed. Also, 
the 6xHis-HBx was very unstable at room temperature and it formed insoluble 
aggregates again when its concentration was greater than 0.4 mg/ml. Moreover, it is 
difficult to remove the histidine-tags after purification. When thrombin was applied to 
remove the 6xHis fusion part, we found that either all proteins precipitated or the 
cleavage was not completed. W e had tried different conditions for thrombin cleavage 
(Table 3.7.1). For example, different amount of thrombin, time allowed for cleavage 
and temperatures provided for the digestion. N o satisfactory digestion results were 
obtained. In contrast, the non-fusion version of HBx was much more stable. After 
refolding, HBx could remain soluble and stable at room temperature when its 
concentration reached 1.8 mg/ml. The gain in stability is mainly due to the removal of 
high molecular weight HBx aggregates, which may promote protein aggregation, by gel 
filtration. The fact that a single gel filtration step can yield a HBx sample of >90% 
purity also provides another advantage — there is no need to express the protein as a 
fusion protein, where subsequent removal of the fusion tags may be problematic. 
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Thrombin Cleavage Parameters Modifications 
Thrombin amount 1U, 2U, 5U & 10U 
Temperature 4。C，22°C & 37oC  
Time allowed 1 h，2h，3h, 4h, 5h & Overnight 
Table 3.8.1 • Different conditions for Thrombin cleavage of 6xHis-HBx 
Different thrombin amount, different temperatures and different time course were 
tried for removal of 6xHis fusion part from HBx. However, proteins either 
precipitated out or the cleavage was not complete. 
3.8.2 High Concentration of DTT was used to Minimize Formation of HBx 
Aggregates 
The major problem encountered during the purification of HBx was the formation of 
inter- or intm-molecular disulfide linkages, which can lead to protein mis folding and 
aggregation. The formation of large molecular weight HBx was shown by the fact 
that HBx eluted as two peaks in the gel filtration profile. W e noticed that the relative 
amount of the first and the second peaks was dependent on the concentration of D T T 
used to solubilize the HBx inclusion bodies. Increasing the concentration of D T T will 
increase the proportion of that monomelic HBx eluted in the second peak. D T T was 
a chemical capable of breaking inter - or intra - disulfide linkages. The experiment 
results implied that D T T might help multimeric HBx to dissociate into monomeric 
form or break the linkage between HBx and other high molecular weight proteins. As 
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high purity of HBx could facilitate subsequent structural experiments and therefore we 
adopted to use 20 m M D T T in dissolving the HBx inclusion bodies. 
3.8.3 Oxidative Refolding to Ensure Proper Disulfide Bond Formation 
Upon refining the refolding method, we found that the buffer pH and the addition of 
different protein stabilizers or solubilizers have important impact on whether the 
protein could successfully refold or not. The system we used for refolding of HBx 
was an oxidative refolding system, which composed of disulfide (GSSG) and thiols 
(GSH). This system has been used extensively for controlling protein disulfide 
formation (Saxena et aL, 1970; Ahmed et ah, 1975). One characteristic of the system is 
that it increases both the rate and the yield of renaturation / reoxidation by facilitating 
rapid reshuffling of incorrect disulfide bonds (Fig 3.8.1). Mixture of oxidized and 
reduced glutathione (GSSG & GSH) was used at concentration of 3 m M to 0.3mM. 
Usually, optimum refolding occurs with a tenfold molar excess of the reduced thiol 
component (Protein Function, 1997). Also, 1 m M of E D T A was added to the 
refolding buffer because it could promote fortuitous oxidation of thiols by molecular 
oxygen (Protein Function, 1997). Sodium chloride (NaCl, 150mM) was added to the 
buffer and the pH of the buffer used was adjusted to 5.4 using sodium acetate. In our 
experience, using a buffer of pH 7.0 or above reduced the stability of HBx, probably 
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because thiol groups are more easily oxidized at alkaline pH. Also, additives such as 
E D TA and NaCl were used because HBx precipitated out once urea was removed when 
E D T A and NaCl were absent. As stated before, the function of E D T A was to 
catalyze fortunate oxidation of thiols by molecular oxygen. For the function of NaCl, 
it provided an environment that optimal electrostatic interactions between charged 
amino acids could build up to stabilize the protein structure. Another refolding 
parameter that needs to be adjusted is the protein concentration. Highly concentrated 
protein solution tends to promote intermolecular aggregation and, therefore, 
unfavorable for refolding. R)r this reason, the HBx concentration was kept below 100 
jig/ml. Each parameter in the refolding of HBx was carefully adjusted, examined and 
many trials were tested to finalize the refolding protocol of HBx. 
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Fig 3.8.1 
The schematic diagram shown the oxidative refolding system used for HBx refolding 
Mixtures of low molecular weight disulfides (GSSG) and thiols (GSH) increase both the rate 
and yield of renaturation I reoxidation by facilitating rapid reshuffling of incorrect disulfide 
bonds (Protein Function, 1997). 
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3.8.4 Computational Prediction and Experimental Prediction of Secondary 
Structure of HBx 
The secondary structure of HBx was predicted by (Figure 3.8.1) PSIPred and was 
compared to that obtained by C D (Table 3.8.2). In both analyses, HBx contains nearly 
20 % of P Sheet. However, the computational prediction of HBx contains 15 % a 
Helix and 67 % Turns & Coils; the experimental estimation reported 30.5 % a Helix 
and 48.5 % Turns & Coils. It appears that computer prediction under estimates the 
helical content of in HBx. It is possible that some coil regions predicted by 
computation methods may actually be a helix. O n the other hand, it should be 
concerned that in both types of secondary structure prediction, HBx contains many 
turns and coils. There was a serine and proline rich region found near the N-terminal 
regions of HBx. This proline-rich region should correspond to the linker region that 
connects the N-terminal regulatory domain to the C-terminal transactivation domain of 
HBx. 
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Structure (%) Computational Prediction Experimental Predication (CDNN) 
(PSIPred)  
g Helix 15% — 3 0 ^ 
p S h e e t ^ m m  
Turns & Coils 67% 
Total Sum 100% 98% 
Table 3.8.2 
Comparison between computational prediction 
(PSIPred) and experimental prediction (CDNN) of HBx 
All secondary structures including a Helix, p Sheet and 
Turns & Coils were listed in percentages. 
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Fig 3.8.2 - Graphic view of HBx secondary structure prediction by PSIPred 
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3.9 Concluding Remarks 
Up to now, information about the structure of HBx was very limited, probably reflect 
the difficulty in obtaining a well-behaved protein sample. The development of 
purification and refolding protocols in the present study should allow a better structural 
characterization of HBx and the interactions with its protein partners in the future. 
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Expression, Purification and Characterization 
Chapter 4 
of Hepatitis B Virus X Interacting Protein (XIP) 
4.1 Introduction 
The HBx-Interacting Protein (XIP) was identified by the yeast two-hybrid system 
through screening a c D N A library derived from a hepatocellular carcinoma cell line 
using a HBx fusion bait (Melegari et al” 1998). XIP is a 9.6 kDa protein can bind HBx 
and its expression inhibits the wild-type hepatitis B virus replication (Melegari et al, 
1998). Their interaction was confirmed by in vitro binding assay using an E. coli system 
to express HBx and GST-XIP proteins (Melegari et al” 1998). The information about 
XII) was very limited, however, this novel protein was widely expressed in various 
human tissues such as heart, brain, placcnta, lung, liver, skeletal muscle, kidney and 
pancreas. Since it was reported that XIP could inhibit H B V replication, how XIP 
interacts with HBx may give hints about the molecular basis of HBx in affecting a cell. 
As a first step to elucidate the structure-function of XIP and its interaction with HBx, 
the expression, purification and structural characterization of XIP were presented in 
this chapter. 
4.2 Consttuction of Recombinant XIP-pET8C 
The D N A fragment encoding the full length of XIP protein was amplified by PGR and 
directionally cloned into the bacterial expression vector pET8C (Novagen) via BamHI 
and Ncol restriction sites, which allow the directional insertion of a D N A sequence to 
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be expressed under the control of a T7 promoter. A start codon A T G is located 
upstream of the insertion site in the case of pET8C. For the XIP-pET8C 
construction, the following oligonucleotides were used: sense 
|5'-TAACTACCATGGAGGCGACCTTGGAG-3'] and anti-sense [5'-TAACTAGGATCCTCAAGAGGCCATTTTGTG-3']. 
For the PGR amplification, 30 cycles consisting of the following steps were used: 94"C 
(30 sec), 55"C (30 sec), 72"C (45 sec) (Fig 4.2.1). Amplified PGR products and the 
vector (pETSC) were digested with BamHI and Ncol (Fig 4.2.2). Then, digested PGR 
products were ligated into pET8C at 14"C overnight. E. coli D H 5 a were transformed 
with the recombinant vectors. Recombinant plasmids D N A isolated from the E. coli 
D H 5 a by minipreparation were analyzed. By comparing the size of recombinant 
vector (Fig 4.2.3) with the original one and finding out fragment size of PGR and 
enzyme digestion screenings (Fig 4.2.4), XIP was successfully cloned into pET8C. 
Finally, the XIP-pET8C clones were confirmed by D N A sequencing (Service Team of 
Department of Biochemistry, CUHK). 
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Fig 4.2.1 • XIP PGR products after 30 cycles PGR reaction 
(Cloning of XIP into pET8C) 
Lane M -100 Base Pair Marker, Lane 1 & 2 - XIP PGR products. 
By comparing with the marker, an expected DNA fragment of size 
around 0.27kb was observed in Lane 1 & 2. 
t 
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Fig 4.2.2 • Restriction digestions of XIP PGR products and pET8C 
(Cloning of XIP into pET8C) 
Lane M -100 Base Pair Marker and Lane M，- X Hind III Marker. Lane 1 & 2 - XIP 
PGR Products digested by BamHI and Ncol, Lane 3 & 4 - pET8C vector digested by 
the same restrictions enzymes as the XIP PGR Product. Using the X Hind III Marker 
as the reference, the double digested vector was of size around 4.6kb that means it 
was linearized and also implied the experimental condition provided could allow 
compete digested of the vectors. 
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Fig 4.2.3 
Screening of transformed clones by comparing the size of 
recombinant vector (XIP-pET8C) with the original vector 
Lane M - X Hind III Marker, Lane 1 - Original pET8C vector 
and Lane 2，3’ 4’ & 5 - XIP-pET8C clones. Noted that the 
recombinant plasmids were of size greater than the original 
vector and this implied that XIP was successfully cloned into 
pET8C. 
Fig 4.2.4 • Screening of transformed clones by PCR and enzyme digestion 
(Cloning of XIP into pET8C) 
Lane M -100 Base Pair Marker. To ensure a PCR reaction is valid, both positive control 
(Lane 1) and negative control were done (Lane 2). Lane 3’ 5，7 & 9 - XIP-pET8C clones 
screened by PCR. DNA fragments of size 0.27kb were amplified in all clones. Lane 4’ 
6，8 & 10 - XIP-pET8C clones screened by BamHI and Ncol restriction digestions, DNA 
fragments of size 0.27kb were cut out in all clones. This two evidences supported the 
XIP was successfully cloned into pET8C. 
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4.3 Expression of XIP in E, coli C41 (DE3) using M9ZB and M9 Mediums 
The recombinant XIP-pET8C plasmid D N A was transformed into E. coli C41 (DE3) for 
the expression of the XIP protein. The E. coli C41 (DE3) transformed with the 
XIP-pET8C was grown in M 9 Z B medium containing ampicillin (100 |Xg/ml) to an 
OD(5QO = 0.4 〜0.6，followed by addition of IPTG to a final concentration of 0.4 m M and 
induced overnight at 37°C. Cells were harvested by centrifugation and lysed by 
sonication. Two aliquots of 30 \l\ bacterial lysate were collected and analyzed in a 15 % 
SDS-PAGE gel (Fig 4.3.1). The remaining bacterial lysate was separated in soluble and 
insoluble fractions by centrifugation at 13,000 x g for 30 min at 4°C. The result of 
SDS-PAGE showed that XIP was expressed mainly as a soluble protein. The 
supernatant containing the XIP protein was directly used for subsequent purification. 
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Fig 4.3.1 - Analysis of the XIP expression and its bacterial lysate 
Lane M - Low Molecular Weight Marker, Lane 1 - Bacterial culture 
before addition of IPTG, Lane 2 - Bacterial culture after 
overnight-induced protein expression, Lane 3 - Whole lysate of XIP, 
Lane 4 - Supernatant of the lysate of XIP and Lane 5 - Pellet of the 
lysate of XIP. 
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4.4 Screening of Chromatographic Conditions for the Purification of XIP 
4.4.1 Introduction 
The HiTrap HIC Selection kit was used to select for the appropriate ligand and 
experimental conditions for XIP purification through hydrophobic interaction 
chromatography. The HiTrap HIC Selection Kit includes five HIC media with different 
hydrophobic characteristics for small-scale media screening and selection. The five 
prepacked HiTrap HIC columns included Phenyl Sepharose High Performance (1 ml), 
Phenyl Sepharose 6 Fast Flow (low sub) (1 ml), Phenyl Sepharose 6 Fast Flow (high sub) 
(1 ml), Butyl Sepharose 4 Fast Flow (1 ml), Octyl Sepharose 4 Fast Flow (1 ml). 
4.4.2 Purification Details 
The soluble fraction of lysate from Section 4.3 was dialyzed overnight in the binding 
buffer (50 m M PB, 1 M (NH,)2S04 and pH 7.0) and was then loaded to the five HIC 
columns in the selection kit. Proteins adsorbed were then eluted with the elution buffer 
(50 m M PB and pH 7.0). Both the wash fractions and the elution fractions were 
collected and analyzed by 15% SDS-PAGE (Fig 4.4.1 a, b, c，d & e). The results of the 
SDS-PAGE analysis showed that XIP bound to all types of HiTrap HIC columns. The 
HiTmp Phenyl High Performance (HP) column was chosen for large-scale purification 
because it gave the sharpest peak upon elution (Fig 4.4.1 d). 
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Fig 4.4.1 a 
Purification of XIP using HiTrap Butyl Sepharose 4 Fast Flow column 
Lane M - Low Molecular Weight Marker，Lane 1 - XIP sample loaded into the column and Lane 
2 - Flow through fraction from the column during sample loading. The wash fractions were 
showed in Lane 3 to Lane 7，it was observed that XIP bound to this type of HIC column. The 
elution fractions were showed in Lane 8 to Lane 12，it was found that XIP was eluted out when 
the buffer condition was changed to a no salt situation. However, the elution resolution was 
quite low because XIP was found in 5 batches of elution fractions. 
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Fig 4.4.1 b 
Purification of XIP using HiTrap Phenyl Sepharose 6 Fast Flow (High Sub) column 
Lane M - Low Molecular Weight Marker, Lane 1 - XIP sample loaded into the column and Lane 
2 - Flow through fraction from the column during sample loading. The wash fractions were 
showed in Lane 3 to Lane 7, it was observed that XIP bound to this type of HIC column. The 
elution fractions were showed in Lane 8 to Lane 12’ it was found that XIP was eluted out when 
the buffer condition was changed to a no salt situation. Unfortunately, the elution resolution 
was low. 
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Fig 4.4.1 c 
Purification of XIP using HiTrap Phenyl Sepharose 6 Fast Flow (Low Sub) column 
Lane M - Low Molecular Weight Marker, Lane 1 - XIP sample loaded into the column and Lane 
2 - Flow through fraction from the column during sample loading. The wash fractions were 
showed in Lane 3 to Lane 7, it was observed that XIP bound to this type of HIC column. The 
elution fractions were showed in Lane 8 to Lane 12, it was found that XIP was eluted out when 
the buffer condition was changed to a no salt situation. However, the elution resolution was 
also low. 





Fig 4.4.1 d 
Purification of XIP using HiTrap Phenyl High Performance column 
Lane M - Low Molecular Weight Marker, Lane 1 - XIP sample loaded into the column and Lane 
2 - Flow through fraction from the column during sample loading. The wash fractions were 
showed in Lane 3 to Lane 7, it was observed that XIP bound to this type of HIC column. The 
elution fractions were showed in Lane 8 to Lane 12，it was found that XIP was eluted out when 
the buffer condition was changed to a no salt situation. All adsorbed XIP was eluted out in the 
first and the second elution fractions. The elution resolution was high when compared with 
other HIC columns. 
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Fig 4.4.1 e 
Purification of XIP using HiTrap Octyl Sepharose 4 Fast Flow column 
Lane M - Low Molecular Weight Marker, Lane 1 - XIP sample loaded into the column and Lane 
2 - Flow through fraction from the column during sample loading. The wash fractions were 
showed in Lane 3 to Lane 7, it was observed that XIP bound to this type of HIC column. The 
elution fractions were showed in Lane 8 to Lane 12, it was found that XIP was eluted out when 
the buffer condition was changed to a no salt situation. The results was same as the other 
HIC columns (except the HiTrap Phenyl HP), the elution resolution was low. 
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4.5 Purification of XIP by HiTrap Phenyl HP 5-ml Column 
After selecting the best column for purification, a large-scale purification of XIP was 
performed with a bacterial supernatant derived from a 1 L culture. The cells were lysed 
and the supernatant containing the XIP was dialyzed overnight in the binding buffer (50 
m M PB, 1 M (NH4)2S04 and pH 7.0), which was then loaded onto the HiTrap Phenyl 
H P column pre-equilibrated with the binding buffer. The adsorbed XIP was eluted at a 
flow rate of 3 ml/min using the elution buffer (50 m M PB, pH 7.0). A gradient elution 
profile was not employed in this column because it could not help us to further purify 
the protein and somewhat broaden the peak upon elution. Fractions collected were 
analyzed by 15 % SDS-PAGE (Fig 4.5.2). The SDS-PAGE showed that XIP was eluted 
at the first three fractions. As XIP was eluted with lots of high molecular weight 
proteins, thus, size exclusion chromatography was used to further purify XIP (Section 
4.6). 
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Fig 4.5.1 - Elution profile of XIP using HiTrap Phenyl HP column 
The binding buffer was 50 m M PB, 1 M (NH4)2S04 and pH 7.0 while the elution buffer was 
50 m M PB and pH 7.0. The flow rate was 3 ml/min and the fraction size was 5 ml/tube. 
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Fig 4.5.2 
Purification of XIP using HiTrap Phenyl High Performance column 
Lane M - Low Molecular Weight Marker, Lane 1 - XIP sample loaded into the column and Lane 
2 - Flow through fraction from the column during sample loading. The elution fractions were 
showed in Lane 3 to Lane 7, it was found that most XIP was eluted out in the & fractions 
and trace of it was present in the fraction. The and fractions were pooled and 
subjected to the next step of purification - gel filtration purification. 
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4.6 Purification of XIP by HiLoad 26/60 Superdex 75 Prep Grade 
(Amersham Pharmacia Biotech, Cat. No.: 17-1071-01) 
The HiLoad 26/60 Superdex 75 Prep Grade column was pre-equilibrated with one bed 
volume of the column buffer (50 m M PB, 150 m M NaCl and pH 7.0). The pooled XIP 
fractions (from Section 4.5) were loaded onto the column. Separation of the XIP 
proteins and other contaminants were achieved according to their difference in size (Fig 
4.6.1). The flow rate was adjusted to 2.5 ml/min. Fractions collected were analyzed 
by 15 % SDS-PAGE (Fig 4.6.2). The XIP was eluted at around 193 ml of the elution 
buffer. Since XIP does not contain any aromatic residues there is no absorbance peak 
at 280 nm. The peak fractions were pooled and were concentrated using Centriprep 
(Millipore, Cat. No.: 4302). The concentration of XIP can be concentrated to 0.8 m M 
〜1 m M . Judging from the SDS-PAGE, the purity of XIP was - 9 0 % (Fig 4.6.3). 
Typical yield of XIP was 15 mg per liter culture of E. coli. The sample was then ready 
for C D spectrum measurement and N M R structural studies. 
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Fig 4.6.1 • Elution profile of XIP using HiLoad 26/60 Superdex 75 Prep Grade column 
The column buffer was 50 m M PB, 150 m M NaCl and pH 7.0. The flow rate was 2.5 ml/min. 
The fraction size was 3 ml/tube. The result of SDS-PAGE showed that XIP was eluted at 
around 193ml (181ml 〜205ml) buffer volume as indicated by the arrow. No absorbance peak 
was observed because XIP does not contain any aromatic residues. 
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Fig 4.6.2 
Purification of XIP using HiLoad 26/60 Seperdex 75 column 
Lane M - Low Molecular Weight Marker, Lane 10 - XIP protein injected into the column and 
Lane 1 to 9 - Fractions 22, 24, 26, 28, 30, 32，34, 36 & 38 collected from the column. 
According to the graph, XIP was eluted at a position of a negative peak because XIP did not 
have any aromatic amino acids and so its absorbance at 280nm was nearly zero. 
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Fig 4.6.3 • XIP was purified and concentrated using centriprep. 
Lane M - Low Molecular Weight Marker. XIP was purified using 
HiLoad 25/60 Superdex 75 column (Lane 1) and concentrated to 0.92 
mM. Lane 2 showed the flow through from Centriprep concentration, 
therefore, nothing was observed. Although XIP purity was 〜88 %, 
the quality was enough for further structural studies such as secondary 
structure prediction by CD spectrum. 
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4.7 Structural Characterization of XIP 
4.7.1 CD Spectrum 
The basic principle of the C D spectrum for secondary structure prediction and analysis 
was discussed in the section 3.7.1. The C D spectrum of XIP was measured and shown 
in Fig. 4.7.1. The C D signals of XIP showed no dominant negative peaks at 222 n m 
and 208 n m (Fig 4.7.1)，indicating that XIP may be unstructured or it does not contain 
any helical contents. 
Fig 4.7.1 • XIP Circular Dichroism Spectrum in 10 mM PB, pH 7.0 
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Fig 4.7.1 - XIP circular dichroism spectrum in 10 mM PB, pH 7.0 
The pattern of the spectrum showed that XIP was unfolded or it did not 
contained any helical structures. It is because the spectrum did not 
have two dominant negative peaks at 222 nm and 208 nm. 
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4.7.2 Chemical Denaturation Experiment of XIP 
C D spectrum of XIP suggests that XIP may be unstructured in vitro. To confirm 
whether XIP had a stable conformation, chemical denaturation experiment was 
performed. XIP was mixed with different concentration of guandium hydrochloride. 
The denaturation curve of XIP was shown in Figure 4.7.2. In contrast to HBx (Figure 
3.7.2), the denaturation curve of XIP did not show a clear two-state transition, 
suggesting that XIP did not showed any cooperative unfolding from a folded state to an 
unfolded state. However, the circular dichroism spectrum is the most sensitive method 
to follow any structural changes in a helix. Therefore, if a protein that does not 
contain any hclical content, e.g. consisting of only P sheet structures, the C D signals will 
be very weak. So, N M R spectroscopy was used to confirm whether the expressed XIP 
contained any folded structure. 
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Fig 4.7.2 • XIP Chemical Denaturation Curve 
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Guandium Hydrochloride (M) in 10 mM PB, pH 7.0 
Fig 4.7.2 - XIP chemical denaturation curve 
The curve pattern showed no clear-cut transition from a folded state to an unfolded state. 
Also, the overall magnitude of the CD signals (Molecular EHipticity) was very small, which 
implied that XIP did not have any conformation in the provided buffer condition. 
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4.7.3 Two-Dimensional Heteronuclear Nuclear Magnetic Resonance (NMR) 
Spectrum of Labeled XIP 
N M R spectroscopy is a powerful technique to study the conformation of biomolecules 
in solution. In a magnetic field, spinning nuclei, as if they behave like magnets, have 
lower energy when aligned with the field than when opposed to it. This energy 
difference is directly proportional to the frequency of the electromagnetic wave absorbed 
and re-emited by the nucleus. The frequency (or chemical shift in N M R terms) of the 
N M R signals of a protein sample is sensitive to the chemical environment local to the 
nuclei (i.e. 'H or '^ N in this case). The chemical shift dispersion in a heteronuclear 
IH」5N correlation spectrum is a good indication to see if a protein contain any stable 
conformation. Each peak in the spectrum corresponds to a H-N functional group of 
backbone amide or the side chain of Asn and Gin. A '^N-labeUed sample of XIP was 
obtained by expressing the protein in M 9 medium supplemented with '^NH.Cl as the 
sole nitrogen source (Appendix VH). The correlation spectrum (Fig. 4.7.3) 
showed that the chemical shift dispersion on the 丨H dimension was smaU (7.8 — 8.5 ppm) 
and close to the random coil values (8.4 ppm), suggesting XII) is unstructured. 
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XIP in 5 0 m M PB, 150mM NaCl , p H 7.0 
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Fig 4.7.3 - 2D Heteronuclear NMR spectrum of XIP in 50 mM PB, 150 mM NaCl and pH 7.0 
Each peak referred to one amino acid residue of XIP. The distribution of the peaks showed that 
they were aggregated together. Therefore, XIP was unfolded in the provided situation. 
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4.8 Discussion 
The novel XIP was found in different human tissues. It was reported to be able to bind 
HBx and inhibits H B V replication (Melegari et al, 1998). Understanding how HBx and 
XIP interact may shed lights on the structural mechanism of how XIP inhibits H B V 
replication. In Chapter 3, we already got refolded HBx proteins that are proved to be 
conformational stable. Certainly, XIP was needed in order to perform in vitro binding 
assays with HBx to elucidate the molecular basis of their interactions. Unfortunately, 
although XIP was expressed in a soluble form, we showed that it is unstructured in both 
C D spectrum and the N M R experiment. There are a lot of reasons that cause a protein 
does not have structure. For example, post-translational modification may be needed to 
fold a protein and some proteins only adopt a stable conformation when they are bound 
to their native interacting partners. Therefore, different protein co-solutes, different 
protein stabilizers and different detergents were added to the XIP proteins to see 
whether we can mimic the cell environment and so XIP can fold properly. In the 
following section, development of XIP purification methods and what we had done to 
solve the problem (XIP had no structure) were discussed. 
4.8.1 Purification Method Development 
In order to obtain a protein with high purity, efforts must be made to find out the proper 
purification strategies of the protein. There was no exception for the XIP purification. 
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Prior to purification of XIP by Hilrap Phenyl HP column and HiLoad 26/60 Superdex 
75 column, other types of columns were tried. For examples, the HiTrap (prepacked) 
lEX Selection Kit provided by Amersham Pharmacia Biotech (Cat. No.: 17-6002-33) was 
tried. This kit included Q Sepharose Fast Flow, SI) Sepharose Fast Flow, C M Sepharose 
Fast Flow, D E A E Sepharose Fast Flow, A N X Sepharose 4 Fast Flow (high sub), Q 
Sepharose X L and SI) Sepharose XL. XIP was not bound to any of these ion exchange 
columns under different pH (data not shown). However, in the case of HiTrap 
(prepacked) HIC Selection Kit (Amersham Pharmacia Biotech, Cat. No.: 17-1349-01), 
XIP bound to all types of HIC columns. Only the HiTrap Phenyl H P column gave the 
highest resolution upon XIP elution (Fig 4.4.1 d). Therefore, HiTrap Phenyl H P 
column was adopted in the first step of XIP purification. Because XIP was a very small 
protein (9.6 kDa) and other bacterial protein contaminants were of a high molecular 
weight (several times greater in size than XIP), size exclusion chromatography was then 
an effective method to purify XIP. 
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4.8.2 Do Different Protein Cosolutes, Protein Stabilizers and Detergents Help 
XIP to Adopt a Stable Conformation? 
Both the C D spectrum and the N M R view of XIP showed that it did not have any 
structure. Actually, different additives that claimed could stabilize protein structure 
(Table 4.8.1) had been used to see whether mimicking the cellular environment can help 
XIP to fold into a native form. For example, 0.5 M Arginine Hydrochloride, 2 m M 
DeoxychoHc Acid, 5 m M DTI； 20 % Glycerol, 0.5 m M to 10 m M SDS, 0.5 M Sodium 
Sulfate, 0.2 M Sucrose and 5 m M Tris-HCl were tried. These additives were commonly 
used as protein structure stabilizer (Arakawa et al, 1995; Stryer et al.�1991; Neugebauer, 
1988; Ames et al., 1999 and Anglister et ai, 1993). However, we still cannot produce a 
structured XIP protein. XIP might require the presence of other proteins to form a 
folded structure. In the cytoplasm, there are lots of different cellular proteins, lipids, 
nutrients, salts and various kinds of oxidative or reductive components. Therefore, it 
was not surprised that XIP could not fold into a native structure in the environment 
provided. Also, the expression system used for XIP production was a prokaryotic 
system. XIP might require post-translational modification to help to fold in a proper 
structure. So, other types of expression systems may try to produce XIP. 
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Protein Cosolutes Potentially Useful Detergents  
Ionic compounds and salts Nonionic 
Na2S04 Dodecyl-p-D-maltoside 
MgS04 Decyl-p-D-maltoside 







Po/yo/s and Sugars MEGA-8 (octanoyl-N-methylglucamide) 
Glycerol MEGA-9 (octanoyl-N-methylglucamide) 
Sucrose MEGA-10 (octanoyl-N-methylglucamide) 
Trehalose Triton X-100 
Glucose Tween 20 
Lactose NonidetP-40 
Inositol /onic 
A— Acids and Derivatives Deoxycholic Acid (Sodium Salts) 
Glycine CTAB 
Alanine (a-, p-) Zwitterionic 
(Sodium) Glutamate CHAPS 
(Potassium) Aspartate LDAO (lauryldimethylamine oxide) 
Arginyl Glutamate ZWITTERGENT 3-08 (N-octylsulfobetaine) 
Arginine Hydrochloride ZWITTERGENT 3-10 (N-decylsulfobetaine) 
Betaine ZWITTERGENT 3-12 (N-dodecylsulfobetaine) 
Sarcosine ZWITTERGENT 3-14 (N-tetradecylsulfobetaine) 
TAMO ZWITTERGENT 3-16 (N-hexadecylsulfobetaine) 
Organic Molecules 
MPD 







I NaN3  
Table 4.8.1 - Common additives that can be used as protein structure stabilizers 
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4.9 Concluding Remarks 
The protein XIP itself did not form structure. All efforts that had been tried to change 
its buffer condition failed to promote structure on XIP. It will be interesting to see if the 
addition of HBx, which is the XIP interacting partner, may help XIP to gain a folded 
structure. Other expression systems or host such as yeast or baculovirus that could 
post-translationally modify XIP through glycosylation, proteolytic cleavage or acylation 
may be tried. 
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Chapter 5 In vivo Studies of HBx and XIP Interactions 
The Hepatitis B Virus X Protein (HBx) and the HBx-Interacting Protein (XIP) were a 
pair of interacting partners. Although HBx was a viral protein, it could interact with 
lots of human cellular proteins. For XIP, it was a novel protein that originates from 
human. However, there is no study concerning the interaction of HBx and XIP in a 
mammalian cell system. We, therefore, aim to study their interactions in vivo using the 
fluorescence resonance energy transfer techniques. Furthermore, we also want to find 
out which region in XII) cxactly interacts with HBx using the yeast two-hybrid system. 
In this Chapter, some preliminary works for in vivo studies of HBx and XIP interactions 
are discussed. 
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5.1 Investigation of Sub-Cellular Localization of HBx and XIP in Liver 
Cells 
5.1.1 Introduction 
The HBx protein was a 16.5 kDa multifunctional protein that was encoded within the 
genome of the HBV. It was believed that HBx was required for viral genome 
transcription and it was also implicated in H C C development. Moreover, the HBx 
exhibited and affected a number of activities including transcription, cell growth and 
apoptotic cell death (Andrisani et al., 1999). However, one proposed biological 
function of XIP was to inhibit HBx activity and thus the replication of H B V (Melegari 
et aL, 1998). Therefore, it may be useful if the sub-cellular localizations of both HBx 
and XIP are known - in which compartment or cellular structure do they interact? In 
this part, both HBx and XIP were cloned into different fluorescent protein vectors and 
the recombinant vectors were transfected into HepG2 cells. The localization of both 
HBx and XIP were investigated. 
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5.1.2 Construction of Recombinant HBx-pECFP-Cl, HBx-pEGFP-Cl, 
HBx-pEYFP-Cl and XIP-pECFP-Cl, XIP-pEGFP-Cl, XIP-pEYFP-Cl 
The D N A fragment encoding the full length of HBx and XIP were amplified by PGR 
and directionally cloned into the mammalian cell expression vectors pECFP-Cl, 
pEGFP-Cl and pEYFP-Cl (Clontech) via Bglll and EcoRI restriction sites. The 
vectors pECFP-Cl, pEGFP-Cl and pEYFP-Cl also have Bglll and EcoRI restriction 
sites, which allow the directional insertion of a D N A sequence to be expressed under 
the control of a p C M V promotor. Both HBx and XIP were cloned in frame with the 
fluorescent protein. For the HBx constructions (HBx-pECFP-Cl, HBx-pEGFP-Cl, 
HBx-pEYFP-Cl), the following oligonucleotides were used: sense 
|5'-TAGGGCAGATCTGCTGCTCGGATGTGCTGCAAACTG-3'] and anti-sense 
[5'-TAGGGCGAATTCTCATTAGGCAGAGGTGAAAAAGTTGCATGG-3']. For the 
constructions of XIP vectors (XIP-pECFP-Cl, XIP-pEGFP-Cl, XIP-pEYFP-Cl), the 
following oligonucleotides were used: sense [5'-TAACTAAGATCTGAGGCGACCTTGGAG-3'] and 
anti-sense [5'-TAACTAGAATTCTCAAGAGGCCATTTTGTG-3'|. The HBx and XIP PGR 
amplification profiles were described in Methodology ffable 2.3.2). Amplified PGR 
products (Fig 5.1.2.1) and vectors were digested with Bglll and EcoRI (Fig 5.1.2.2). 
Then, digested PGR products were ligated into pECFP-Cl, pEGFP-Cl and pEYFP-Cl. 
D H 5 a E. coli cells were transformed with the recombinant vectors. Recombinant 
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plasmid D N A isolated from the D H 5 a by minipreparation was analyzed by PGR 
screening and 1 % agarose gel electrophoresis (Fig 5.1.2.3 a, b & c). By comparing the 
size of the amplified D N A fragments with the marker, HBx and XIP were successfully 
cloned into pECFP-Cl, pEGFP-Cl and pEYFP-Cl. Finally，the HBx-pECFP-Cl, 
HBx-pEGFP-Cl, HBx-pEYFP-Cl and XIP-pECFP-Cl, XIP-pEGFP-Cl, 
XIP-pEYFP-Cl clones were confirmed by D N A sequencing (Service Team of 
Department of Biochemistry, CUHK). 
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Fig 5.1.2.1 - HBx and XIP PGR products after 30 cycles PGR reaction 
(Cloning of HBx and XIP into fluorescence protein vectors) 
Lane M -100 Base Pair Marker. Lane 1 & Lane 4 - Negative control for the 
PGR reaction. By comparing with the marker, an expected DNA fragment of 
size around 0.27kb for XIP and 0.27kb for HBx was observed in Lane 2 & 3 
and 5 & 6 respectively. 
• 
Fig 5.1.2.2 
Restriction digestions of HBx & XIP PGR products, pECFP-C1, pEGFP-C1 and pEYFP-C1 
Lane M - 100 Base Pair Marker and Lane M，- \ Hind III Marker. All PGR products and 
vectors were double digested by Bglll and EcoRI. The digested HBx and XIP P G R products 
were showed in Lane 4 & 5 and Lane 9 & 10 respectively. Digested vectors for HBx cloning 
including pECFP-C1，pEGFP-C1 and pEYFP-C1 were showed in Lane 1’ 2 & 3 respectively. 
For XIP subcloning, digested vectors were showed in Lane 6，7 & 8 for pECFP-C1，pEGFP-C1 
and pEYFP-C1 respectively. 
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Fig 5.1.2.3 • Screening of transformed clones by PCR 
(Cloning of HBx and XIP into fluorescence protein vectors) 
Lane M -100 Base Pair Marker, in all sets of PCR screening, both negative control (Lane 1) 
and positive control (Lane 2) were performed, (a) Lanes 3 to 7 - Transformed clones for 
HBx-pEGFP-C1. (b) Lanes 3 to 7- Transformed clones for HBx-pECFP-C1 and Lane 8 to 
12 - Transformed clones for HBx-pEYFP-C1. (c) Lanes 3 to 7 - Transformed clones for 
XIP-pECFP-C1, Lanes 8 to 12- Transformed clones for XIP-pEGFP-C1 and Lanes 13 to 15 
-Transformed clones for XIP-pEYFP-C1. DNA fragments of expected size (0.47kb for 
HBx and 0.27kb for XIP) were amplified in some of the transformed clones. The clones 
that were proved to harbor HBx I XIP fragments were then confirmed by DNA sequencing. 
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5.1.3 Transfection of pEGFP-Cl HBx and pEGFP-Cl XIP into HepG2 to 
Find Out HBx and XIP Sub-Cellular Localization 
5.1.3.1 Introduction 
The pEGFP-Cl encodes a red-shifted variant of wild-type GFP, which has been 
optimized for brighter fluorescence and brighter expression in mammalian cells. 
Fusions to the C terminus of E G F P retain the fluorescent properties of the native 
protein allowing the localization of the fusion protein in vivo. In this experiment, the 
target genes (HBx and XIP) were cloned into pEGFP-Cl in frame with the E G F P 
coding sequences. The recombinant E G F P vectors were transfected into mammalian 
cells using Lipofectamine and Plus Reagent. Details of transfection were reported in 
the part of methodology (section 2.9.1). 
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5.1.4 Investigation of EGFP Proteins Expression using the Confocal 
Microscope and the Leica TCS Software 
After 24 hours of transfection, the cells were recovered and protein expressions were 
allowed to take place. The cells that were seeded on the slips were collected, fixed by 
3.7% formaldehyde and mounted on slides using 30% glycerol. The confocal 
microscope and the Leica TCS software for data collection were employed for 
investigation of the expression pattern of EGFP, EGFP-HBx and EGFP-XIP in HepG2 
cells. The expression pattern of E G F P was used as the control (Fig 5.1.4.1). It was 
found that the HBx was highly localized in the nucleus and some cellular structures in 
the cytoplasm (Fig 5.1.4.2). However, some structures inside the nucleus did not stain 
with any HBx proteins (Fig 5.1.4.2). For XIP, its expression pattern was the same as the 
control (Fig 5.1.4.3) and, therefore, no information on sub-cellular localization of XIP 
was obtained. 
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Fig 5.1.4.1 
Photos showed the expression pattern of EGFP in HepG2 after 24 hours of transfection 
EGFP was expressed in all around (both cytoplasm and the nucleus) inside HepG2. 
mam 
Fig 5.1.4.2 
The expression pattern of HBx-EGFP in HepQ2 after 24 hours of transfection 
HBx-EGFP was all expressed in all around (both cytoplasm and the nucleus) inside HepG2. 
When compared with the control (EGFP expression pattern), HBx was highly localized in the 
nucleus and some cellular structures in the cytoplasm. However, some structures inside the 
nucleus did not stained with any HBx proteins 
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Fig 5.1.4.3 
The expression pattern of XIP-EGFP in HepG2 after 24 hours of transfection 
XIP-EGFP was all expressed in all around (both cytoplasm and the nucleus) inside HepG2. 
When compared with the control (EGFP expression pattern), XIP expression pattern was 
similar to that of the control. This might imply that XIP followed the EGFP expression 
pattern. However, further investigation should be done in the future. 
I l l 
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5.1.4 Discussion and Future Prospects 
HBx is localized in both the nucleus and the cytoplasm. This phenomenon was valid 
because HBx acts as transact!vator and so it was transported to the nucleus once formed. 
Also, it could affect downstream pathway of cell protection mechanism and therefore it 
was also found in the cytoplasm. For XIP, no information was obtained about its 
localization in cells as the pattern of XIP expression was the same as that of the control. 
It might be due to the fact that XIP had no conformation and so it was unfolded inside 
the cell and thus it followed the EGFP localization. It will be interesting to 
co-transfect both HBx and XIP-EGFP plasmids into the cells to see if XIP interacts 
with HBx and if the co-transfection will change the pattern of sub-cellular localization. 
Also, other cell type, e.g. Hep3B, may be used. The vectors constructed will be used 
in the future to perform the FRET (Fluorescence Resonance Energy Transfer) 
experiments between HBx and XIP. If HBx and XIP interacts at the cellular level, 
excitation of the fluorephore on HBx will in turn excite the fluorephore on XIP and vice 
versa. All these works can help us to elucidate the localization of XIP and to confirm 
the interaction b etween HBx and X IP. M oreover, propidium iodide (PI) that c an 
penetrate cell membranes of dead cells and intercalates into double-stranded nucleic 
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acids will be employed to stain the nucleus of the transfected cells. The purpose is to 
ensure which compartmentation in cells that HBx and XIP are localized. 
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5.2 Interaction of HBx and XIP by Yeast Two-Hybrid System 
5.2.1 Introduction 
To confirm the interaction of HBx and XIP by yeast two-hybrid system, HBx was cloned 
into pGBKT7, which coded for a D N A binding domain while XIP was cloned into 
pACT2, which coded for an activation domain. Two-hybrid system takes advantage of 
the fact that many eukaryotic transcription factors have two domains, a D N A binding 
domain and an activation domain. The D N A binding domain anchors the transcription 
factor to the D N A at a sequence specific site. The activation domain turns on gene 
expression by interacting with the transcription complex. If HBx and XIP interact with 
each other, they will bring the D N A binding domain and the activation domain into close 
proximity and will turn on the reporter genes. 
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5.2.2 Constfuction of Recombinant HBx-pGBKT7 and XIP-pACT2 Plasmids 
The recombinant HBx-pGBKT7 construct was provided by Miss H. Chan. The D N A 
fragment encoding the full length of XIP protein was amplified by PGR methodology 
and directionally cloned into the bacterial expression vector pACT2 via BamHI and Ncol 
restriction sites. The vector pACT2 also had BamHI and Ncol restriction sites, which 
allow the directional insertion of a D N A sequence to be expressed under the control of 
constitutive A D H l promoter. A GAL4-AD encoding sequence is located upstream of 
the insertion site in pACT2. For this XIP construction (XIP-pACT2), the following 
oligonucleotides were used: sense |5'-TAACTACCATGGAGGCGACCTTGGAG-3'] and anti-sense 
|5'-TAACTAGGATCCTCAAGAGGCCATTTTGTG-3'|. For the PGR amplification, 30 cycles consisting 
of the following steps were used: 94"C (30 sec), 55"C (30 sec), ITC (45 sec) (Fig 5.2.2.1). 
Amplified PGR products and pACT2 were digested with BamHI and Ncol (Fig 5.2.2.2). 
Then, digested PGR products were ligated into pACT2 at 14"C overnight. D H 5 a E. coli 
cells were transformed with the recombinant vectors. Recombinant plasmid D N A 
isolated from the D H 5 a by minipreparation was analyzed by PGR & enzyme digestion 
screening and agarose gel electrophoresis (Fig 5.2.2.3). By comparing the size of the 
PCR and enzyme digestion products, XIP was successfully cloned into pACT2. Finally, 
the pACT2 clones were confirmed by D N A sequencing (Service Team of Department 
of Biochemistry, CUHK). 
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Fig 5.2.2.1 • XIP PGR products after 30 cycles PGR reaction 
(Cloning of XIP into pACT2) 
Lane M was the 250 Base Pair Marker, Lane 1 & 2 were negative control for 
the PGR reaction. An expected DNA fragment of size around 0.27kb was 
amplified and observed in Lanes 3 to 6. 
Fig 5.2.2.2 • Restriction digestions of XIP PGR products and pACT2 
Lane M -100 Base Pair Marker. Both the PGR products and the vector were digested 
by BamHI and Ncol. Digested XIP fragments were showed in Lane 1 & 2 while 
digested pACT2 were showed in Lane 3 to 6. 
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Fig 5.2.2.3 a 
Screening of transformed clones by comparing the size of 
recombinant vector (XIP-pACT2) with the original vector (pACT2) 
Lane M - 100 Base Pair Marker, Lane 1 - Original pACT2 vector and 
Lanes 2 to 13 - XIP-pACT2 clones. Noted that the recombinant 
plasmids were of size greater than the original vector and this implied 
that XIP was successfully cloned into pACT2. 
• • • 
Fig 5.2.2.3 b • Screening of transformed clones by PCR and enzyme digestion 
(Cloning of XIP into pACT2) 
Lane M -入 Hind III Marker, Lane 1, 3，5, 7’ 9, 11’ 13’ 15，17 & 19 - XIP-pACT2 
clones screened by PCR. DNA fragments of size 0,27kb were amplified in all 
clones. Lane 2, 4，6, 8’ 10, 12, 14, 16’ 18 & 20 - XIP-pACT2 clones screened by 
restriction digestion. DNA fragments of size 0.27kb were cut out in all clones. 
This two evidences supported the XIP was successfully cloned into pACT2. The 
clone of XIP-pACT2 was then further confirmed by DNA sequencing. 
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5.2.3 Confirmation of HBx and XIP Interaction by the Yeast Two-Hybrid 
System 
The competent cell of yeast strain Y187 was prepared according to the protocol 
described in the part of methodology (section 2.9.2.1). The recombinant constructs 
were transformed into the aliquots of competent cells. Five sets of co-trans formation 
experiments were performed with combination of different constructs: Positive control 
(pVA3-l & pTDl-l)，Negative controls (pGBKTT & pACT2’ HBx-pGBKT7 & pACT2， 
p G B K T 7 & XIP-pACT2) and the HBx-pCiBKT7 & XIP-pACT2. After 
transformation, all transformed cells were resuspended in 0.2 ml of IX T E and spread 
on SD/-Lcu/-Trp plates, which were incubated at a 30"C incubator for a few days. 
Yeast colonies were grown on the plates. When colony size became large enough (〜 
2 m m in diameter), P-galactosidase Colony Lift Assay was performed. Sterile filter 
paper was presoaked in Z buffer/ X-gal solution in 90 m m Petri dish. Another clean 
filter paper was placed to rub colonies onto the plate. The rubbed filter paper with 
colonies was placed to a pool of liquid nitrogen to submerge for about 10 scconds to 
lyse the cells to release the enzyme P-galactosidase (if the two genes interact with each 
other). The paper was then placed with colonies side up on presoaked filter paper and 
incubated at 30"C. The appearance of blue color was checked from 30 minutes to 8 
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hours. The presence of blue colonies will imply that the two proteins interact with each 
other. Positive control gave blue colonies and negative controls gave colonies with no 
color change. The transformation procedure and the interaction system (pGBKTT & 
pACT2) were valid and of good efficiency. However, HBx did not interact with XIP 
(Fig 6.3.1 e). The same experiment was repeated two more times and the same result 
was observed. 
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pVA3-l and pTDl-1 pGBKT7 and pACT2 
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pGBKT7-HBx and pACT2-XIP Fig 5.2.4 - Preliminary Experiment of 
HBx and XIP Interaction by Yeast 
. , \ Two-Hybrid System 
# ‘ The Positive Control pVA3-1 & pTD1-1 (a) 
M showed blue colonies, the Negative 
m <： Controls pGBKT7 & pACT2 (b), 
醒 ’ pGBKT7-HBx & pACT2 (c) and pGBKT7 & 
m ^： PACT2-XIP (d) showed colonies with no 
m； ^ ‘ color change. The pGBKT7-HBx & 
二. , pACT2-XIP (e) pair also showed a negative 
'、. result. This might imply that HBx and XIP 
(®) did not interact or the system provided did 
not favor their interaction. 
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5.2.4 Discussion 
The interaction between HBx and XIP was not detected by our yeast two-hybrid system. 
The discrepancy between our results and those reported in literature (Melegari et aL, 1998) 
could be due to the following reasons: 
(1) The yeast two-hybrid system used was different from the one used that for discovery of HBx and 
XIP interaction. The basic principles of the two yeast two-hybrid assays were the 
same - The transcriptional regulators used contain a DNA-binding domain 
(DNA-BD) that binds to a specific promoter sequence and an activation domain 
(AD) that directs the U N A polymerase II complex to transcribe the gene 
downstream of the DNA-binding site (Keegan et aL, 1986; Hope et aL, 1986; Ma et aL, 
1987). Both domains are requked to activate a gene. If the D N A - B D and A D 
can be brought into close physical proximity in the promoter region, the 
transcriptional activation function will be activated. W e used the system composed 
of HBx fused with the GAL4 DNA-binding domain while XIP fused with the G A L 4 
activation domain and the reporter genes included MELl, lacZ, A D E 3 and HIS3 
(Fig 5.2.4.1). For the original authors, their system composed of HBx fused with 
the LexA Protein (i.e. D N A binding domain) while XIP fused with the B42 
activation domain and the reporter genes included lacZ and L E U Z (Fig 5.2.4.2). 
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(2) U is also possible that different variant of H Bx was used. W e were not able to contact the 
original authors of the paper (Melegari et al., 1998) to obtain the strain information 
of HBx they used. 
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Fig 5.2.4.1 一 The schematic diagram showed the yeast two-hybrid system used GAL4 
DNA-binding domain and the GAL4 activation domain interacting fusion pairs 
The reporter genes included MEL1, lacZ, ADE3 and HIS3. 
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Fig 5.2.4.2 - The schematic diagram showed the yeast two-hybrid system used Lex A 
protein DNA-binding domain and the B42 activation domain interacting fusion pairs 
The reporter genes included lacZ and LEU3. 
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Conclusion 723 
.Chapter 6 Conclusion 
W e have developed an efficient expression and purification systems for HBx and XIP, 
with typical yield of proteins in the range of 15-20 mg per liter culture of E. coll. HBx 
was expressed in E. coli. Strain C41 (DE3) as insoluble protein and was purified in an 
unfolded state by HiJ.oad 26/60 Superdex 200 Prep Grade column and refolded 
through oxidative refolding. XIP was expressed in E. coli. Strain C41 (DE3) as a 
soluble protein, which was purified by HiTrap Phenyl H P column and HiLoad 26/60 
Superdex 75 Prep Grade column. Purification of large amount of both proteins 
allows characterization of their structures using biophysical methods. The circular 
dichroism (CD) and the chcinical denaturation experiments showed that refolded HBx 
‘ adopts a stable conformation. The C D spectrum of HBx suggested that the protein 
adopts -30% helix and -20% sheet. The chemical denaturation curve of HBx 
resembles a two-state transition and its stability, measured by free energy of unfolding, 
was 13 kj/mol at 25°C. O n the other hand, XIP was found to be unstructured by C D 




I Sequence of HBx and XIP 
The H B x sequence and its corresponding amino acid sequence was showed below: 
1 ATG GCT GCT CGG ATG TGC TGC AAA CTG GAT CCT TCG CGG GAC GTC 45 
1 Met Ala Ala Arg Met Cys Cys Lys Leu Asp Pro Ser Arg Asp Val 15 
46 CTT TGT TTA CGT CCC GTC GGC GCT GAA TCC CGC GGA CGA CCC CTC 90 
16 Leu Cys Leu Arg Pro Val Gly Ala Glu Ser Arg Gly Arg Pro Leu 30 
91 TCG GGG CCG CTT GGG ACT CTC TCG TCC CCT TCT CCG TCT GCC GTT 135 
31 Ser Gly Pro Leu Gly Thr Leu Ser Ser Pro Ser Pro Ser Ala Val 45 
136 CCA GCC GAC CAC GGG GCG CAC CTC TCT TTA CGC GGT CTC CCC GTC 180 
46 Pro Ala Asp His Gly Ala His Leu Ser Leu Arg Gly Leu Pro Val 60 
181 TGT GCC TTC TCA TCT GCC GGT CCG TGT GCA CTT CGC TTC ACC TCT 225 
61 Cys Ala Phe Ser Ser Ala Gly Pro Cys Ala Leu Arg Phe Thr Ser 75 
22 6 GCA CGT TGC ATG GAG ACC ACC GTG AAC GCC CAT CAG ATC CTG CCC 270 
7 6 Ala Arg Cys Met Glu Thr Thr Val Asn Ala His Gin lie Leu Pro 90 
271 AAG GTC TTA CAT AAG AGG ACT CTT GGA CTC CCA GCA ATG TCA ACG 315 
91 Lys Val Leu His Lys Arg Thr Leu Gly Leu Pro Ala Met Ser Thr 105 
316 ACC GAC CTT GAG GCC TAG TTC AAA GAC TGT GTG TTT AAG GAC TGG 360 
106 Thr Asp Leu Glu Ala Tyr Phe Lys Asp Cys Val Phe Lys Asp Trp 120 
361 GAG GAG CTG GGG GAG GAG ATT AGG TTA AAG GTC TTT GTA TTA GGA 405 
121 Glu Glu Leu Gly Glu Glu lie Arg Leu Lys Val Phe Val Leu Gly 135 
406 GGC TGT AGG CAT AAA TTG GTC TGC GCA CCA GCA CCA TGC AAC TTT 450 
136 Gly Cys Arg His Lys Leu Val Cys Ala Pro Ala Pro Cys Asn Phe 150  
451 TTC ACC TCT GCC TGA 462 
151 Phe Thr Ser Ala END 
• Hepatitis B Virus X Protein (HBx) consists lots of variants; our HBx belongs to Human hepatitis B virus adn4 
subtype. 
• Sequence in red color refers to the start codon 
• Sequence in orange color refers to the stop codon 
The XIP sequence and its corresponding amino acid sequence was showed below: 
1 ATG GAG GCA ACT TTG GAG CAG CAT TTG GAG GAC ACA ATG AAG AAT 45 
1 Met Glu Ala Thr Leu Glu Gin His Leu Glu Asp Thr Met Lys Asn 15 
4 6 CCA TCC ATT GTT GGA GTC CTA TGC ACA GAT TCA CAA GGA CTT AAT 90 
16 Pro Ser lie Val Gly Val Leu Cys Thr Asp Ser Gin Gly Leu Asn 30 
91 CTG GGC TGC CGT GGT ACC CTG TCC GAT GAG CAT GCT GGA GTG ATA 135 
31 Leu Gly Cys Arg Gly Thr Leu Ser Asp Glu His Ala Gly Val lie 45 
136 ACT GTT CTA GCC CAG CAG GCA GCT AAG CTA ACC TCT GAC CCC ACC 18 0 
4 6 Thr Val Leu Ala Gin Gin Ala Ala Lys Leu Thr Ser Asp Pro Thr 60 
181 GAC ATC CCT GTG GTA TGT TTA GAA TCA GAT AAT GGG AAC ATT ATG 225 
61 Asp lie Pro Val Val Cys Leu Glu Ser Asp Asn Gly Asn lie Met 75 
226 ATC CAG AAA CAC GAT GGC ATC ACA GTG GCT GTG CAC AAA ATG GCC 270 
76 lie Gin Lys His Asp Gly lie Thr Val Ala Val His Lys Met Ala 90 
Til TCT TGA 276 ~ “  
91 Ser End. 
• Sequence in red color refers to the start codon 
• Sequence in orange color refers to the stop codon 
Appendix n 
n Vector Sequences 
(A) pRESTA Vector Sequence, Invittogen (Modified) 
1 GAT CTC GAT CCC GCG AAA TTA ATA CGA CTC ACT ATA GGG AGA CCA 45 
4 6 CAA CGG TTT CCC TCT AGA AAT AAT TTT GTT TAA CTT TAA GAA GGA 90 
91 GAT ATA CAT ATG GGA TCC GAG CTC GAC ATC TGC AGC TGG TAG CAT 135 
Met Gly Ser Glu Leu Asp lie Cys Ser Trp Tyr His 12 
136 GGA ATT CGA AGC TTG ATC CGG CTG CTA ACA AAG CCC GAA AGG AAG 180 
13 Gly lie Arg Ser Leu lie Arg Leu Leu Thr Lys Pro Glu Arg Lys 27 
181 CTG AGT TGG CTG CTG CCA CCG CTG AGC AAT AAC TAG CAT AAC CCC 225 
28 Leu Ser Trp Leu Leu Pro Pro Leu Ser Asn Asn 42 
226 TTG GGG CCT CTA AAC GGG TCT TGA GGG GTT TTT TGC TGA AAG GAG 270 
271 GAA CTA TAT CCG GAT CTG GCG TAA TAG CGA AGA GGC CCG CAC CGA 315 
316 TCG CCC TTC CCA ACA GTT GCG CAG CCT GAA TGG CGA ATG GGA CGC 360 
361 GCC CTG TAG CGG CGC ATT AAG CGC GGC GGG TGT GGT GGT TAG GCG 405 
406 CAG CGT GAC CGC TAG ACT TGC CAG CGC CCT AGC GCC CGC TCC TTT 450 
4 51 CGC TTT CTT CCC TTC CTT TCT CGC CAC GTT CGC CGG CTT TCC CCG 495 
4 96 TCA AGC TCT AAA TCG GGG GCT CCC TTT AGG GTT CCG ATT TAG AGC 54 0 
541 TTT ACG GCA CCT CGA CCG CAA AAA ACT TGA TTT GGG TGA TGG TTC 585 
586 ACG TAG TGG GCC ATC GCC CTG ATA GAC GGT TTT TCG CCC TTT GAC 630 
631 GTT GGA GTC CAC GTT CTT TAA TAG TGG ACT CTT GTT CCA AAC TGG 675 
67 6 AAC AAC ACT CAA CCC TAT CGC GGT CTA TTC TTT TGA TTT ATA AGG 720 
721 GAT TTT GCC GAT TTC GGC CTA TTG GTT AAA AAA TGA GCT GAT TTA 765 
7 66 ACA AAT ATT TAA CGC GAA TTT TAA CAA AAT ATT AAC GTT TAC AAT 810 
811 TTC GCC TGA TGC GGT ATT TTC TCC TTA CGC ATC TGT GCG GTA TTT 855 
856 CAC ACC GCA TAC AGG TGG CAC TTT TCG GGG AAA TGT GCG CGG AAC 900 
901 CCC TAT TTG TTT ATT TTT CTA AAT ACA TTC AAA TAT GTA TCC GCT 945 
94 6 CAT GAG ACA ATA ACC CTG ATA AAT GCT TCA ATA ATA TTG AAA AAG 990 
991 GAA GAG TAT GAG TAT TCA ACA TTT CCG TGT CGC CCT TAT TCC CTT 1035 
1036 TTT TGC GGC ATT TTG CCT TCC TGT TTT TGC TCA CCC AGA AAC GCT 1080 
1081 GGT GAA AGT AAA AGA TGC TGA AGA TCA GTT GGG TGC ACG AGT GGG 1125 
1126 TTA CAT CGA ACT GGA TCT CAA CAG CGG TAA GAT CCT TGA GAG TTT 1170 
1171 TCG CCC CGA AGA ACG TTT TCC AAT GAT GAG CAC TTT TAA AGT TCT 1215 
1216 GCT ATG TGA TAC ACT ATT ATC CCG TAT TGA CGC CGG GCA AGA GCA 1260 
1261 ACT CGG TCG CCC CCC GCG GTA TTC TCA GAA TGA CTT GGT TGA GTA 1305 
1306 CTC ACC AGT CAC AGA AAA GCA TCT TAC GGA TGG CAT GAC AGT AAG 1350 
1351 AGA ATT ATG CAG TGC TGC CAT AAC CAT GAG TGA TAA CAC TGC GGC 1395 
1396 CAA CTT ACT TCT GAC AAC GAT CGG AGG ACC GAA GGA GCT AAC CGC 14 4 0 
14 41 TTT TTT GCA CAA CAT GGG GGA TCA TGT AAC TCG CCT TGA TCG TTG 1485 
1486 GGA ACC GGA GCT GAA TGA AGC CAT ACC AAA CGA CGA GAG TGA CAC 1530 
1531 CAC GAT GCC TGT AGC AAT GCC AAC AAC GTT GCG CAA ACT ATT AAC 1575 
1576 TGG CGA ACT ACT TAC TCT AGC TTC CCG GCA ACA ATT AAT AGA CTG 1620 
1621 AAT GGA GGC GGA TAA AGT TGC AGG ACC ACT TCT GCG CTC GGC CCT 1665 
1666 TCC GGC TGG CTG GTT TAT TGC TGA TAA ATC TGG AGC CGG TGA GCG 1710 
Appendix III 
1711 TGG GTC TCG CGG TAT CAT TGC AGC ACT GGG GCC AGA TGG TAA GCG 1755 
1756 CTC CCG TAT CGT AGT TAT CTA CAC GAC GGG GAG TCA GGC AAC TAT 1800 
1801 GGA TGA ACG AAA TAG ACA GAT CGC TGA GAT AGG TGC CTC ACT GAT 1845 
1846 TAA GCA TTG GTA ACT GTC AGA CCA AGT TTA CTC ATA TAT ACT TTA 1890 
1891 GAT TGA TTT AAA ACT TCA TTT TTA ATT TAA AAG GAT CTA GGT GAA 1935 
1936 GAT CCT TTT TGA TAA TCT CAT GAC CAA AAT CCC TTA ACG TGA GTT 1980 
1981 TTC GTT CCA CTG AGC GTC AGA CCC CGT AGA AAA GAT CAA AGG ATC 2025 
2026 TTC TTG AGA TCC TTT TTT TCT GCG CGT AAT CTG CTG CTT GCA AAC 2070 
2071 AAA AAA ACC ACC GCT ACC AGC GGT GGT TTG TTT GCC GGA TCA AGA 2115 
2116 GCT ACC AAC TCT TTT TCC GAA GGT AAC TGG CTT CAG CAG AGC GCA 2160 
2161 GAT ACC AAA TAG TGT CCT TCT AGT GTA GCC GTA GTT AGG CCA CCA 2205 
2206 CTT CAA GAA CTC TGT AGC ACC GCC TAG ATA CCT CGC TCT GCT AAT 2250 
2251 CCT GTT ACC AGT GGC TGC TGC CAG TGG CGA TAA GTC GTG TCT TAG 2295 
2296 CGG GTT GGA CTC AAG ACG ATA GTT ACC GGA TAA GGC GCA GCG GTC 2340 
2341 GGG CTG AAC GGG GGG TTC GTG CAC ACA GCC CAG CTT GGA GCG AAC 2385 
238 6 GAC CTA CAC CGA ACT GAG ATA CCT ACA GCG TGA GCT ATG AGA AAG 2430 
24 31 CGC CAC GCT TCC CGA AGG GAG AAA GGC GGA CAG GTA TCC GGT AAG 2475 
2476 CGG CAG GGT CGG AAC AGG AGA GCG CAC GAG GGA GCT TCC AGG GGG 2520 
2521 AAA CGC CTG GTA TCT TTA TAG TCC TGT CGG GTT TCG CCA CCT CTG 2565 
2566 ACT TGA GCG TCG ATT TTT GTG ATG CTC GTC AGG GGG GCG GAG CCT 2610 
2611 ATG GAA AAA CGC CAG CAA CGC GGC CTT TTT ACG GTT CCT GGG CTT 2655 
2656 TTG CTG GCC TTT TGC TCA CAT GTT CTT TCC TGC GTT ATC CCC TGA 2700 
2701 TTC TGT GGA TAA CCG TAT TAG CGC CTT TGA GTG AGC TGA TAG CGC 2745 
274 6 TCG CCG CAG CCG AAC GAC CGA GCG CAG CGA GTC AGT GAG CGA GGA 2790 
27 91 AGC GGA AGA GCG CCC AAT ACG CAA ACC GCC TCT CCC CGC GCG TTG 2835 
2836 GCC GAT TCA TTA ATG CAG 2853 
• Sequence in red color refers to the start codon 
• Sequence in purple color rrfers to the BamHI cloning site which would lead to two addition amino acids at the 
N-terminal of the HBx and XIP proteins 
« 
Appendix IV 
(B) pRESTA Vector Sequence, Invitrogen (With exHis and Thrombin cleavage site, Modified) 
1 GAT CTC GAT CCC GCG AAA TTA ATA CGA CTC ACT ATA GGG AGA CCA 45 
4 6 CAA CGG TTT CCC TCT AGA AAT AAT TTT GTT TAA CTT TAA GAA GGA 90 
91 GAT ATA CAT ATG CGG GGT TCT CAT CAT CAT CAT CAT CAT GGT CTG 135 
Met Arg Gly Ser His His His His His His Gly Leu 12 
136 GTT CCG CGT GGA TCC GAG CTC GAC ATC TGC AGC TGG TAC CAT GGA 180 
13 Val Pro Arg Gly Ser Glu Leu Asp lie Cys Ser Trp Tyr His Gly 27 
181 ATT CGA AGC TTG ATC CGG CTG CTA ACA AAG CCC GAA AGG AAG CTG 225 
28 lie Arg Ser Leu lie Arg Leu Leu Thr Lys Pro Glu Arg Lys Leu 4 2  
226 AGT TGG CTG CTG CCA CCG CTG AGC AAT AAC TAG CAT AAC CCC TTG 270 
43 Ser Trp Leu Leu Pro Pro Leu Ser Asn Asn 
271 GGG CCT CTA AAC GGG TCT TGA GGG GTT TTT TGC TGA AAG GAG GAA 315 
316 CTA TAT CCG GAT CTG GCG TAA TAG CGA AGA GGC CCG CAC CGA TCG 360 
361 CCC TTC CCA ACA GTT GCG CAG CCT GAA TGG.CGA ATG GGA CGC GCC 405 
406 CTG TAG CGG CGC ATT AAG CGC GGC GGG TGT GGT GGT TAC GCG CAG 450 
451 CGT GAC CGC TAC ACT TGC CAG CGC CCT AGC GCC CGC TCC TTT CGC 495 
496 TTT CTT CCC TTC CTT TCT CGC CAC GTT CGC CGG CTT TCC CCG TCA 540 
541 AGC TCT AAA TCG GGG GCT CCC TTT AGG GTT CCG ATT TAG AGC TTT 585 
586 ACG GCA CCT CGA CCG CAA AAA ACT TGA TTT GGG TGA TGG TTC ACG 630 
631 TAG TGG GCC ATC GCC CTG ATA GAC GGT TTT TCG CCC TTT GAC GTT 675 
676 GGA GTC CAC GTT CTT TAA TAG TGG ACT CTT GTT CCA AAC TGG AAC 720 
721 AAC ACT CAA CCC TAT CGC GGT CTA TTC TTT TGA TTT ATA AGG GAT 765 
7 66 TTT GCC GAT TTC GGC CTA TTG GTT AAA AAA TGA GCT GAT TTA ACA 810 
811 AAT ATT TAA CGC GAA TTT TAA CAA AAT ATT AAC GTT TAC AAT TTC 855 
856 GCC TGA TGC GGT ATT TTC TCC TTA CGC ATC TGT GCG GTA TTT CAC 900 
901 ACC GCA TAC AGG TGG CAC TTT TCG GGG AAA TGT GCG CGG AAC CCC 945 
946 TAT TTG TTT ATT TTT CTA AAT ACA TTC AAA TAT GTA TCC GCT CAT 990 
991 GAG ACA ATA ACC CTG ATA AAT GCT TCA ATA ATA TTG AAA AAG GAA 1035 
1036 GAG TAT GAG TAT TCA ACA TTT CCG TGT CGC CCT TAT TCC CTT TTT 1080 
1081 TGC GGC ATT TTG CCT TCC TGT TTT TGC TCA CCC AGA AAC GCT GGT 1125 
1126 GAA AGT AAA AGA TGC TGA AGA TCA GTT GGG TGC ACG AGT GGG TTA 1170 
1171 CAT CGA ACT GGA TCT CAA CAG CGG TAA GAT CCT TGA GAG TTT TCG 1215 
1216 CCC CGA AGA ACG TTT TCC AAT GAT GAG CAC TTT TAA AGT TCT GCT 1260 
1261 ATG TGA TAC ACT ATT ATC CCG TAT TGA CGC CGG GCA AGA GCA ACT 1305 
1306 CGG TCG CCC CCC GCG GTA TTC TCA GAA TGA CTT GGT TGA GTA CTC 1350 
1351 ACC AGT CAC AGA AAA GCA TCT TAC GGA TGG CAT GAC AGT AAG AGA 1395 
1396 ATT ATG CAG TGC TGC CAT AAC CAT GAG TGA TAA CAC TGC GGC CAA 14 4 0 
14 41 CTT ACT TCT GAC AAC GAT CGG AGG ACC GAA GGA GCT AAC CGC TTT 1485 
1486 TTT GCA CAA CAT GGG GGA TCA TGT AAC TCG CCT TGA TCG TTG GGA 1530 
1531 ACC GGA GCT GAA TGA AGC CAT ACC AAA CGA CGA GAG TGA CAC CAC 1575 
1576 GAT GCC TGT AGC AAT GCC AAC AAC GTT GCG CAA ACT ATT AAC TGG 1620 
1621 CGA ACT ACT TAC TCT AGC TTC CCG GCA ACA ATT AAT AGA CTG AAT 1665 
1666 GGA GGC GGA TAA AGT TGC AGG ACC ACT TCT GCG CTC GGC CCT TCC 1710 
1711 GGC TGG CTG GTT TAT TGC TGA TAA ATC TGG AGC CGG TGA GCG TGG 1755 
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1756 GTC TCG CGG TAT CAT TGC AGC ACT GGG GCC AGA TGG TAA GCG CTC 1800 
1801 CCG TAT CGT AGT TAT CTA CAC GAC GGG GAG TCA GGC AAC TAT GGA 1845 
1846 TGA ACG AAA TAG ACA GAT CGC TGA GAT AGG TGC CTC ACT GAT TAA 1890 
1891 GCA TTG GTA ACT GTC AGA CCA AGT TTA CTC ATA TAT ACT TTA GAT 1935 
1936 TGA TTT AAA ACT TCA TTT TTA ATT TAA AAG GAT CTA GGT GAA GAT 1980 
1981 CCT TTT TGA TAA TCT CAT GAC CAA AAT CCC TTA ACG TGA GTT TTC 2025 
202 6 GTT CCA CTG AGC GTC AGA CCC CGT AGA AAA GAT CAA AGG ATC TTC 2070 
2071 TTG AGA TCC TTT TTT TCT GCG CGT AAT CTG CTG CTT GCA AAC AAA 2115 
2116 AAA ACC ACC GCT ACC AGC GGT GGT TTG TTT GCC GGA TCA AGA GCT 2160 
2161 ACC AAC TCT TTT TCC GAA GGT AAC TGG CTT CAG CAG AGC GCA GAT 2205 
2206 ACC AAA TAG TGT CCT TCT AGT GTA GCC GTA GTT AGG CCA CCA CTT 2250 
2251 CAA GAA CTC TGT AGC ACC GCC TAG ATA CCT CGC TCT GCT AAT CCT 2295 
2296 GTT ACC AGT GGC TGC TGC CAG TGG CGA TAA GTC GTG TCT TAG CGG 2340 
2341 GTT GGA CTC AAG ACG ATA GTT ACC GGA TAA GGC GCA GCG GTC GGG 2385 
2386 CTG AAC GGG GGG TTC GTG CAC ACA GCC CAG CTT GGA GCG AAC GAC 2430 
2431 CTA CAC CGA ACT GAG ATA CCT ACA GCG TGA .GCT ATG AGA AAG CGC 2475 
24 7 6 CAC GCT TCC CGA AGG GAG AAA GGC GGA CAG GTA TCC GGT AAG CGG 2520 
2521 CAG GGT CGG AAC AGG AGA GCG CAC GAG GGA GCT TCC AGG GGG AAA 2565 
2566 CGC CTG GTA TCT TTA TAG TCC TGT CGG GTT TCG CCA CCT CTG ACT 2610 
2 611 TGA GCG TCG ATT TTT GTG ATG CTC GTC AGG GGG GCG GAG CCT ATG 2655 
2656 GAA AAA CGC CAG CAA CGC GGC CTT TTT ACG GTT CCT GGG CTT TTG 2700 
2701 CTG GCC TTT TGC TCA CAT GTT CTT TCC TGC GTT ATC CCC TGA TTC 2745 
2746 TGT GGA TAA CCG TAT TAG CGC CTT TGA GTG AGC TGA TAG CGC TCG 27 90 
2791 CCG CAG CCG AAC GAC CGA GCG CAG CGA GTC AGT GAG CGA GGA AGC 2835 
2836 GGA AGA GCG CCC AAT ACG CAA ACC GCC TCT CCC CGC GCG TTG GCC 2880 
2881 GAT TCA TTA ATG CAG 2895 
• Sequence in red cobr refers to the start codon 
• Sequence in green color refers to the His-Tagfusion protein 
• Sequence in blue color refers to the thrombin cutting site 
Appendix VI 
n Vector Maps 
M imm -mm TUT 
Tl(.二一""T ^^-p 0 
The pRSETA vector map was showed above. It was modified as the 6x His, XpressTM Epitope and EK were deleted. 
It could be regarded as a mini-pRSETA. The T7 promoter, RBS, ATG, MCS, f1 origin, Ampicillin resistance gene and 
pUC origin still remain unchanged. However, additional GGA TCC (Amino Acid = Gly Ser) was added due to 
modification and sub-cloning. 
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The pRSETA (6x His) vector map was showed above. It was modified as the Xpress™ Epitope and EK were 
deleted. It could be regarded as a mini-pRSETA (6x His). The T7 promoter, RBS, ATG, 6x His, MCS, f1 origin, 
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The pET8C (pET-3d) vector map was showed above. It included T7 promoter, RBS, T7-Tag, ATG, MCS， 
T7 terminator and Ampicillin resistance gene. The details of MCS (cloning I expression region) was 
showed on the figure below: 
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^ ^ i ^ f 1^ 47111 The PECFP-C1 vector map was showed 
y ^ u c •丨 on the left. It encoded an enhanced cyan 
/ fluorescent variant of the Aequorea 
� p p � —� Victoria green fluorescent protein gene 
£co0 l09 l - ^ J / poh'A p p p p ^ \： (GFP). The ECFP gene contained six 
J ^ ^ 4 7 I amino acid substitutions, which enhanced 
r ‘ SV40 the brightness and solubility of the protein, 
\ \ Kan'/ . , ^ , . J ‘ .… 
\ \ Neo' f i / / \ primarily due to improved protein-folding 
\ V f}淑 ori p on^/ ^ y i ^ properties and efficiency of chromophore 
\ \ / 力们I formation. The details of MCS were 
showed on the figure below: 
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I The pEGFP-C1 vector map was showed on the 
, / l e t The PEGFP-C1 encoded a red-shifted 
y ^ / ' ori V \ variant of wild-type GFP, which had been 
/ /H^^'TK EGFX M optimized for brighter fluorescence and higher 
£co0 l09 K g I poly a' f 广 f P r i te^ expression in mammalian cells. pEGFP-Cl 
TT U k h ^ BstQ I encoded a GFPmutI variant, which contained 
W ” ‘ p o M / ^ P ^ Q g the double amino acid substitution. The 
\ \ f.j0o^  I, / J \ coding sequence contained more than 190 
\ � o ' p slient bases changed to human codon-usage 
Mhi I preferences. So, the translation efficiency of 
J ^ T DraIII EGFP mRNAin eukaryotic cells was increased. 
Sta I The details of MCS were showed on the figure 
below: 
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I The pEYFP-C1 vector map was showed 
Nhe\ on the left. It encoded an enhanced 
/ yellow-green variant of the Aequorea 
/ ^ o ^ r f ^ T X 力沒el Victoria green fluorescent protein gene 
\ \ (GFP). The EYFP gene contained four 
/HS*' TK ryrp \ A 
£goOl09 K ^ j poK'A \ amino acid substitutions and upstream 
pEYFP-Cl J - 权 s ⑷ 丨 sequences flanking EYFP had been 
SV40 ^ ^ ^ 二 converted to a Kozak consensus 
\ f 广 V A , / * ^ M C S translation initiation site. These changes 
\ oh 尹 ori / increased the translational efficiency of the 
Afn\ YFP mRNA and consequently the 
expression of EYFP in mammalian cells. 
5如 I The details of MCS were showed on the 
figure below: 
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‘""xl III 
. , . , , , , / " The pGBKT7 vector map was showed on the left. 
— T h e pGBKT7 vector expressed proteins fused to 
/ 叫 " ' " ^ G A L ^ S L amino acids 1-147 of the GAL4 DNA binding 
/ /-pot dna-BD^^^ j domain (DNA-BD). In yeast, fusion proteins 
were expressed at high levels from the 
p G B K T 7 ‘ III constitutive ADH1 promoter {Padhi)] transcription 
I 7.3 k l i was terminated by the T7 and ADH1 transcription 
y iJJI： / termination signals (Tt? & /^ om). pGBKT7 also 
\ 2h / contained the T7 promoter, a c-Myc epitope tag, 
Kail' K ^ X and a MCS. pGBKT7 replicated autonomously in 
E. coli from the pUC. The vector carried the 
Kanr for selection in E. coli and the TRP1 
A c -Myc epitope tag nutritional marker for selection in yeast. The 
details of MCS were showed on the figure below: 
MATti<MAKCr<!- LHA ClViKtfir 
，丨舰Sa關―…丨, fe為拟L似Ei"丨^ 
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A . A . 17 Gminrndmif timet ， 
* T； Proinotor ^ c f/yc i:pi:opi> T.iq 
GTA ATA CGA CTC ACT ATA GGG CGA GCC GCC ATC m GAG GAG CAG AAG CTG ATC TCA GAC GAG GAC C/G 
START 
•J'XI：：' 
ATG GCC ATG GAG GCC GAA TTC CCG GGG ATC CG T CGA CCT GCA GCG GCC GCA [ ^ C 巻 : A T A A C C C C . 
航 I iVcffI Sf)l fcofil s層 |‘  ff柳HI Sir/1 Pit I STOP STOP 
)试； T , Xjml 
» T/ Tcfimiixor 
TTGGGGCC TCTAAAC G G GTCTTGAG GG G T T ^ T FG CG CGC TTG CAG C CAhG C TAA TTCCG G G CG.WTTTC TTA TGATTT 
STOP 
ATG ATTT n A T T A T T A A A T M G TTA TA^>AAAHAH TAhG TGTATACA.HAJ TTTAAAG TGACTC TT.AG 6 TTTTAAA-ACGAHAA 
, 'J LtiJ* GL 丨mi Ptimit 
LUA DL ViHtor 
In-am Gritn«itn« ； 
/ ... JTfaal 
V " • 一 … r 、 \ 
imp' 入-、 
wcs 1 / V 
* 銜(丨：\ /C.:lt \ 
H A epitope ‘ / 丨： 、 
〜 \ 丨 • pACT2 ,..1-, 
“ ， 胸 _ — / 
Xrnal I / / 
\ r , / 
SflCl /(、、\ ,V”一人 Xfwl / H.‘r^nH ； I � 
舞询” / 勒r: 
如. 
The pACT2 vector map was showed on the left. pACT2 generated a fusion of the GAL4 AD (amino acids 768-881), a HA epitope 
tag, and a protein of interest cloned into the MCS in the correct orientation and reading frame. The hybrid protein was 
expressed at high levels in yeast host cells from the constitutive ADH1 promoter (P); transcription was terminated at the ADH1 
transcription termination signal (7). The protein was targeted to the yeast nucleus by the nuclear localization sequence from SV40 
T-antigen which had been cloned into the 5' end of the GAL4 AD sequence. pACT2 was a shuttle vector that replicated 
autonomously in E. coli and carried the Ampr for selection in E. coli and the LEU2 nutritional marker for selection in yeast. 
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IV Electrophoresis Markers 
I • 
-、双(、‘ I 
^ H H H • - • 
I… I 
100 Base-Pair Ladder X DNA-H/nd m Digest 
(Amersham Pharmacia Biotech, (Amersham Pharmacia Biotech, 
Cat. No.: 27-4001-01) Cat. No.: 27-4048-01) 







LMW-SDS Marker Kit 
(Amersham Pharmacia Biotech, 
Cat. No.: 17-0446-01) 
Appendix XII 
V Agarose Gel Electrophoresis 
• 50x TAB Buffer 
242 g of Iris base (SIGMA) 
57.1 ml of glacial acetic acid 
100 ml of 0.5 M E D T A (pH 8.0) 
Add water up to 1 L 
• Ethidium Bromide (10 mg/ml) 
Add 1 g of ethidium bromide to 100 ml water and stir for several hours; wrap the 
container with aluminum foil and store at room temperature 
• 6x DNA Dye 
0.25X (w/v) bromophenol blue 
40% (w/v) sucrose in H,〇 
Use water for preparation 
Appendix XIII 
VI SDS-PAGE Electrophoresis 
• 2x SDS Loading Buffer (store at -20"C) 
100 mmol/L of Tris H Q , pH 6.8 
200 mmol/L of D T T 
4% of SDS (w/v) 
0.2% of Bromophenol Blue (w/v) 
20% of glycerol 
• 4x Separating Gel Buffer, pH 8.8 
36.4 g of Tris Base 
8 ml of 10% SDS 
Add water up to 200 ml and adjust pH to 8.8 (Don't Back Titrate) 
• 4x Stacking Gel Buffer, pH 6.8 
12 g of Iris Base 
8 ml of 10% SDS 
Add water up to 200 ml and adjust pH to 6.8 (Don't Back Titrate) 
• 10% Ammonium Persulphate (APS) 
10% of APS (w/v) m water 
• lOx SDS Running Buffer (IL) 
30.2 g of Tris Base 
188 g of Glycine 
100 ml of 10% SDS (w/v) 
Add water up to 1 liter 
Appendix XIV 
• Protein Gel Recipe for 2 BioRad Mini Gels 
• Separating Gel 
Steek Solution Final Acrylamide Concentration in Separating Gel (%) 
15 % 12.5 % 7.5% 
DistilledH2O 1.9 ml 2.5 ml 3.7 ml 
4 X Tris-Cl / SDS 
(pH 8.8) 2.0 ml 2.0 ml 2.0 ml 
30 % Acrylamide 4.0 ml 3.3 ml 2.0 ml 
10% APS 100 |al 100^1 100 |al 
TEMED ^ 4|ul 4 
• Stacking Gel 
Stock Solution Final Acrylamide Concentration in Stacking Gel (%) 
‘ J% 
DistiUedHp ^ 
4 X Tris-Cl/SDS 
, 0 . 8 9 ml (pH 6.8) 
30 % Acrylamide 0.6 ml 
10% APS 50 Hi 
TEMED 4 
• Staining Solution 
Components 200 ml 500 ml TL 
0.15 0/0 Commassie 0.3 g 0.75 g 15 g 
Blue R 250 
30%Ethanol 60 ml 150 ml 300 ml 
10 % Acetic Acid 20 ml 50 ml 1()() ml 
Distilled H2O 120 ml 300 ml 600 ml 
Appendix XV 
VD Mediums for Bacterial Culture 
• M9ZB Medium 
NH4HCI 1 g/L 
KH2PO4 3 g/L 
Na2Hl)04 6 g/L 
NaCl 5 g/L 
Trypton lOg/L 
Autoclave and then cool down to ~50°C, add the folio wings: 
20% glucose 20 ml/L 
1 M MgS04 1 ml/L 
• Concentrated M9 Medium and Supplements 
5X Concentrated M9 salts: 
Anhydrous Di-Sodium I lydrogen Phosphate (Na2HP04) 64g 
Potassium Di-Hydrogen Phosphate (KH2PO4) 15g 
Sodium Chloride (NaCl) 2.5g 
—Dissolve in 1 L of water and autoclave 
Solution Q: 
Concentrated Hydrochloric acid (5M) (HCl) 8ml 
Iron Chloride (FeCb • 4H2O) 5g 
Calcium Chloride (CaCb • 2H2O) 184mg 
Boric Acid (I “BO3) 64mg 
Cobalt Chloride (C0CI2 • 6H2O) 18mg 
Copper Chloride (CuCb . 2I I2O) 4mg 
Zinc Chloride (ZnCl�） 340mg 
Sodium Salt of Molybdic Acid (Na2Mo()4 • 2I I2O) 6()5mg 
Manganse chloride (MnCb • 4H2O) 4()mg 
—Make up 1 L with water and filter sterile 
Vitamin Mixture 
Thiamine 5()mg 
d-Biotin (Stored at 4。C) lOmg 
Choline Chloride lOmg 
Folic Acid lOmg 
Niacinamide K)mg 
D-Pantothenic Acid (Stored at 0-4"C) lOmg 
Pyridoxal (Stored at -2()°C) l()mg 
Riboflavin lOmg 
—Make up to 100ml and filter sterile 
Appendix Xvi 
• Production of lxM9 medium + Ampicillin 
To 780ml of autoclaved water in an autoclaved flask add: 
200ml of 5X Concentrated M9 Salts 
2ml of IM MgSO, 
2ml of Solution Q 
Ig of NH4CI dissolved in 5ml of H^O and filter sterile 
10ml of Vitamin Mix 
500ml of O.lg / ml Ampicillin (filter sterilize & store at -20°C) 
Carbon source: 
Hlter sterilized glucose solution 6g/L 
(or 4g/L when using CI3 glucose) 
5ml of autoclaved glycerol 
(or 4g when using CI3 glycerol) 
Appendix XVII 
Vni Medium and Buffers for Cell Culture 
• PBS (Dulbecco，s Phosphate-Buffered Saline), lOX stock solution 
115 g of Na^HPC^ 
39.6 g of NaH^PO^ 
58.4 g of NaCI 
Add water up to 1 L, pH is adjusted to 7.4 with HCl 
Sterilize by autoclave and store at 4 °C 
• RPMI1640 Medium (IL) 
1 pack of RPMI powder (For 1 Litre medium) 
4.78 g of HEPES 
2 g of NaHCO, 
Add sterile water up to IL and adjust pH to 7.2 with HCl or N a O H 
Sterilize by filtration through Steritop bottle top filter units with 0.22 |Lim Durapore 
(PVDF) membrane and store at 4 °C 
• Propidium Iodide (PI) DNA Staining Solution 
0.1% of Triton X-100 
lOmM ofEDTA (pH7.4) 
50 [ig/ml of propidium iodide 
400 [ig/ml of Ribonuclease A (Rnase A) 
Use PBS for preparation and the solution is pre-chilled at 4 °C before use 
Appendix XVIII 
IX Medium for Yeast Culture 
• YPDA Medium (IL) 
2()g/L of peptone 
lOg/L of yeast extract 
20g/L of agar (For Y P D A plates) 
Add water up to 950ml and adjust pH to 5.8, sterile by autoclave 
Cool down to ~ 55"C, add the followings: 
50ml of 40% glucose, 15 ml of 0.2% adenine hemisulfate 
• Synthetic Dropout (SD) Medium (100 ml) 
0.67 g of yeast nitrogen base without amino acid 
2 g of agar (For plates only) 
Add the different dropout powders for different dropout medium / plates: 
0.074 g of TRP D O supplement 
0.064 g of TRP, -LEU D O supplement 
0.062 g of rilP, -LCU, - HIS D O supplement 
0.064 g of TRP, -LEV, -HIS, -ADE D O supplement 
Add water up to 85 ml, adjust pH to 5.8，sterile by autoclave 
Cool down to 〜55"C, add 5 ml of 40% glucose 
Appendix XIX 
X Buffers for Yeast Transformation 
• Stock Solutions For Yeast Transformation 
50% PEG 8000 (Polyethylene glycol 8000) 
250g P E G in 500ml water and sterile by autoclave 
lOx TE Buffer 
0.1 M Tris-HCl, lOmM EDTA, adjust pH to 7.5 and sterile by autoclave 
lOx LiAc Buffer 
1 M JiAc, adjust pH to 7.5 by acetic acid and sterile by autoclave 
• Working Solutions For Yeast Transformation 
Ix TE/LiAc Buffer (1600/M) 
160 |al of lOx TE + 160 |LI1 of lOx liAc + 1280 |ul of Autoclaved water 
PEG/LiAc Buffer (10 ml) 
8 ml of 50% P E G + 1 ml of lOx TE + 1 ml of lOx LiAc 
Ix TE Buffer (10 ml) 
1 ml of lOx I E + 9 ml of Autoclaved water 
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